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Abstract
This review highlights recent evidence from clinical and basic science studies supporting a role for estrogen in neuroprotection.
Accumulated clinical evidence suggests that estrogen exposure decreases the risk and delays the onset and progression of
Alzheimer’s disease and schizophrenia, and may also enhance recovery from traumatic neurological injury such as stroke.
Recent basic science studies show that not only does exogenous estradiol decrease the response to various forms of insult, but
the brain itself upregulates both estrogen synthesis and estrogen receptor expression at sites of injury. Thus, our view of the role
of estrogen in neural function must be broadened to include not only its function in neuroendocrine regulation and reproductive
behaviors, but also to include a direct protective role in response to degenerative disease or injury. Estrogen may play this
protective role through several routes. Key among these are estrogen dependent alterations in cell survival, axonal sprouting,
regenerative responses, enhanced synaptic transmission and enhanced neurogenesis. Some of the mechanisms underlying these
eects are independent of the classically defined nuclear estrogen receptors and involve unidentified membrane receptors, direct
modulation of neurotransmitter receptor function, or the known anti-oxidant activities of estrogen. Other neuroprotective eects
of estrogen do depend on the classical nuclear estrogen receptor, through which estrogen alters expression of estrogen responsive
genes that play a role in apoptosis, axonal regeneration, or general trophic support. Yet another possibility is that estrogen
receptors in the membrane or cytoplasm alter phosphorylation cascades through direct interactions with protein kinases or that
estrogen receptor signaling may converge with signaling by other trophic molecules to confer resistance to injury. Although there
is clear evidence that estradiol exposure can be deleterious to some neuronal populations, the potential clinical benefits of
estrogen treatment for enhancing cognitive function may outweigh the associated central and peripheral risks. Exciting and
important avenues for future investigation into the protective eects of estrogen include the optimal ligand and doses that can
be used clinically to confer benefit without undue risk, modulation of neurotrophin and neurotrophin receptor expression,
interaction of estrogen with regulated cofactors and coactivators that couple estrogen receptors to basal transcriptional
machinery, interactions of estrogen with other survival and regeneration promoting factors, potential estrogenic eects on
neuronal replenishment, and modulation of phenotypic choices by neural stem cells. 7 2000 Elsevier Science Ltd. All rights
reserved.
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1. Introduction
The rush over the last decade to elucidate the neuro-
protective eects of estrogen in disease or injury of the
nervous system was precipitated by a series of findings
which forced recognition of the potential impact of
gonadal steroid hormones in disturbances of the ner-
vous system. Key among these findings was the clear
statistical bias toward either men or women in the inci-
dence and recovery from neurological damage and
mental disorders. Additionally, new tools were devel-
oped which allowed the mapping of estrogen receptors
outside of the brain regions responsible for reproduc-
tion. Collectively, the evidence has led to a growing
appreciation that the positive impact of estrogen on
neurite outgrowth and neuronal survival in the hypo-
thalamus might have more generalized applicability
than was previously widely recognized.
Until the late seventies and early eighties, soon after
morphological sex dierences in the brain were first
recognized in birds and mammals, the possible eects
of estrogen on areas of the nervous system outside of
those regions specifically involved in reproduction were
often either unrecognized or disregarded as being irre-
levant. Basic studies in neuroscience typically used
mixed sex groups until it was appreciated that this
induced a high degree of variability into the results of
specific experiments. After that time, most researchers
elected to use exclusively males for their studies,
because they considered that experimental designs
which took into account female cyclicity were too
cumbersome to attempt, unless, of course, the subject
of study was a specific aspect of female physiology or
behavior. Societal issues that allowed disregard for dis-
orders more prevalent in women, beliefs that humans
are less susceptible to hormonal influences than other
species, as well as extensive arguments within the
medical community for biological vs cultural causation
in psychiatric disturbances, may all have played a role
in the traditional lack of appreciation of hormones as
a possible positive influence in neurological and mental
disorders. Potentially important hormone-dependent
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sex dierences in specific disorders and in responses to
therapeutic interventions were thus largely ignored.
Although still controversial in some arenas, the idea
that estrogen and other gonadal hormones may play a
role in neuroprotection has gained general acceptance
and is the subject of ever increasing investigation. A
potential complication, but ultimate benefit, in examin-
ing the therapeutic role of estrogen in neuroprotection
comes from the development of selective estrogen
receptor modulators (SERMS) that target one estrogen
sensitive tissue over another; the specific actions of
SERMS in the nervous system will need to be evalu-
ated, but SERMS may ultimately be useful in targeting
neuroprotective actions of estrogen analogs, while not
activating neuroendocrine functions.
Although epidemiological and basic science studies
point to estrogen as an important factor in neuropro-
tection, proving such a role in clinical studies is not
simple, for several important biological reasons. The
functions of estrogen are intimately associated with
those of progesterone and androgen, making it dicult
to consider each independently with respect to neuro-
protection. Estrogen regulates expression of both pro-
gestin (Thornton et al., 1986; Warembourg et al.,
1986; Blaustein et al., 1988; DonCarlos et al., 1989;
Bethea et al., 1992) and androgen (Handa et al., 1986,
1996; McAbee and DonCarlos, 1999a, 1999b) intra-
cellular receptors, so that biologically relevant eects
of progestin and androgen may depend on prior ex-
posure to estrogen. Furthermore, testosterone is a pre-
cursor for estrogen synthesis, and the enzyme
responsible for this conversion, aromatase, is expressed
in the brain (Naftolin, 1994; Lephart, 1996; Celotti et
al., 1997; Balthazart and Ball, 1998; Hutchison et al.,
1999). During development, steroid hormone exposure
may permanently alter the susceptibility to specific
neurodegenerative diseases or alter recovery of func-
tion from traumatic episodes so that estrogen may
have dierent eects in females and males due to
dierential sensitivity to the hormone. Genetic risk for
certain diseases may be greater in males when genes on
the X chromosome have an impact on the disease.
Finally, because estrogen lowers cholesterol and alters
immune function, the role of estrogen in neuroprotec-
tion may be indirect, through actions on other organs
which then impinge upon the health of the brain.
A final introductory comment is that the term neu-
roprotection refers not to a single phenomenon but
rather encompasses a spectrum of independent pro-
cesses. Estrogen directly promotes cell survival, pro-
motes synaptic plasticity, and prevents axonal and
dendritic pruning. Estrogen can also prevent malfunc-
tion of neurons by altering levels of neurotransmitters,
neurotransmitter receptors, and second messengers.
This regulation of neurotransmitter function can then,
secondarily, promote cell survival and neurite branch-
ing. Thus, the protective eects of estrogen are multi-
faceted (Fig. 1). In this review, the primary, though
not exclusive, focus is on the role of estrogen in cell
survival.
2. Neuroprotective eects of estrogen
2.1. Clinical studies
Estrogen has been associated with a decreased risk,
delayed onset and progression, or enhanced recovery
from numerous traumatic or chronic neurological and
mental diseases, some of which are discussed below.
These span many dierent types of disease and
trauma, ages, and hormonal status, and can be var-
iously classified as dysfunction due to abnormal devel-
opment (dyslexia, autism), abnormal neurotransmitter
systems (depression; anorexia/bulimia), disorders
caused by trauma (stroke, epilepsy, head injury), or
disorders caused by abnormal immune (multiple scler-
osis) or cardiovascular (stroke, head injury) function.
The etiology of some disorders that are slowed or alle-
viated by estrogen is unknown (Alzheimer’s disease,
Parkinson’s disease, sleep disorders). Some of these
disorders are sexually dierentiated in children,
suggesting an eect of steroid hormones during devel-
opment. Others present at times of altered hormonal
status such as puberty, pregnancy or menopause, or
increase with age. In the various sections below,
selected examples of disorders and diseases for which
there has been a preponderance of discussion or data
suggesting a sex dierence or estrogenic component in
protection are discussed. The specific cellular mechan-
isms involved in estrogen dependent neuroprotection
are discussed in later sections.
Fig. 1. Mechanisms that may be involved in neuroprotection by
estradiol. The hormone may directly aect cell survival or prevent
cell death by acting on cell death cascades. In addition, estradiol
may promote cell survival by the induction of axonal sprouting of
injured axons, by augmenting regeneration of damaged neural con-
nections and by promoting synaptic transmission.
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2.1.1. Stroke
Stroke is a leading cause of mortality and morbidity
in the population over middle age (reviewed in Paga-
nini-Hill, 1995). Estrogen is thought to protect against
stroke in humans, but whether this occurs throughout
life, and the precise mechanisms estrogen might use to
provide protection, are unclear. Men and women do
not dier with respect to the primary risk factors for
stroke, which are age and high blood pressure. Men
and women do dier, however, with respect to the
incidence of stroke, with premenopausal women hav-
ing fewer strokes and dierent types of strokes than
observed in age matched men; after menopause, the
incidence of stroke increases in women compared to
age matched premenopausal women. Most strokes
(80%) are due to cerebral infarct, the type of stroke
most common in men. Subarachnoid hemorrhages are
less common, but occur with higher frequency in
women than in men (Kertesz and Benke, 1989; Paga-
nini-Hill, 1995). In part, these dierences appear to be
due to the eects of endogenous estrogen on lowering
of cholesterol levels and on vascular endothelium, pro-
tective eects that are lost in postmenopausal women.
Dierences in the inflammatory response may also
contribute to the sex dierences in response to infarct
(Li et al., 1994) The observations from epidemiological
studies that moderate exposure to exogenous estrogen
may decrease the risk of stroke (discussed below),
together with the finding that tamoxifen (an estrogen
receptor antagonist) treatment confers increased risk
for stroke in women (Gail et al., 1999) lend credence
to the idea that estrogen plays a protective role in cer-
ebrovascular disease. However, pregnancy and child-
birth are associated with an increased risk of stroke.
The National Institute for Neurologic Disorders and
Stroke (1999) reported that the risk of ischemic stroke
is nine times higher and hemorrhagic stroke 28 times
higher during the first 6 weeks of postmartum, but the
cause is not known.
High dose oral contraceptives, such as the prep-
arations used before the 1980s, were associated with
increased risk for stroke in premenopausal women, but
the preparations now in use contain less estrogen, and
are not associated with any increased risk for either
ischemic or hemorrhagic stroke (Petitti et al., 1996,
1998; Chang et al., 1996). Paganini-Hill (1995)
reviewed epidemiological studies that assessed the
impact of estrogen replacement therapy on the relative
risk for stroke. Many of the reports are conflicting;
some have not demonstrated any eect of postmeno-
pausal hormone use on stroke risk (eg, Petitti et al.,
1998). However, the majority of studies have shown
that continued use of estrogen, and to a lesser extent,
former use of estrogen, reduces the risk of stroke by
an average of 50% (e.g. Paganini-Hill et al., 1988;
Falkeborn et al., 1993; Longstreth et al., 1994). Simi-
larly, at least one estrogen receptor antagonist, tamoxi-
fen, increases the risk of stroke (Gail et al., 1999). A
magnetic resonance imaging and neuropsychiatric
study found a lower incidence of asymptomatic
ischemic brain damage in postmenopausal women tak-
ing estrogen compared with those who did not, but no
association between the extent of white matter damage
and cognitive test results (Schmidt et al., 1996). Since
risk appears to depend on the type and amount of es-
trogen used, it is clear that clinical trials to determine
the precise consequences of endogenous and exogenous
steroid exposure in conferring the risk of stroke will
need to be carefully designed. The potential negative
influences of estrogen or estrogen receptor antagonists
may restrict the use of estrogen as a preventative
measure for stroke to a particular cohort of women.
Earlier studies have reported that the retention of
verbal abilities is better in female stroke victims than
in male stroke victims (reviewed in Kertesz and Benke,
1989), and that women experience a better recovery
from aphasia than do men (Pizzamiglio et al., 1985),
possibly due to dierences in laterality or initial verbal
fluency. Subsequent studies have altered this view:
although the incidence of infarct may be higher in men
than in women, among stroke patients with similar
lesion size and location, no clear-cut sex dierences
exist in the frequency of aphasia (Kertesz and Shep-
pard, 1981; Kertesz and Benke, 1989; Hier et al.,
1994), or prognosis for recovery of verbal fluency
(Sarno et al., 1985; Schehter et al., 1985; Pedersen et
al., 1995). On other measures, such as contralateral
spatial neglect, men fare better than women when the
right hemisphere is damaged (McGlone et al., 1997).
Nevertheless, since basic science discoveries have
pointed to the involvement of circulating and exogen-
ous estrogen levels in the size of the lesion and recov-
ery from experimentally induced stroke, estrogen may
exert direct neuroprotective eects that limit damage
to neurons following ischemia episodes in humans as
well (see Section 2.2.2).
2.1.2. Alzheimer’s disease
Alzheimer’s disease aicts more women than men,
has an earlier onset in women, and progresses more
rapidly in women. Many epidemiological studies have
pointed to the protective role of estrogen in Alzhei-
mer’s disease. One extensive clinical study assessing the
protective role of estrogen in Alzheimer’s disease was
conducted by Paganini-Hill and Henderson (1996).
This study was based on postmortem follow-up reports
of almost 4000 women who had answered a health sur-
vey that was administered, on average, 5 years before
death. They found an inverse relationship between es-
trogen use and Alzheimer’s disease; the risk of Alzhei-
mer’s disease decreased with increasing dose and
duration of estrogen replacement therapy. Exogenous
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estrogen treatment appears to be the key, because
there was no relationship between Alzheimer’s disease
and age at menarche or age at the last menstrual
period, although higher body weight, and therefore
presumably higher levels of estrogen due to formation
in adipose tissue, conferred some decreased risk for
Alzheimer’s disease. Results of many other epidemiolo-
gical studies are in agreement in demonstrating an
inverse relationship between estrogen use and Alzhei-
mer’s disease (e.g. Tang et al., 1996; Yae et al., 1998;
Costa et al., 1999; Slooter et al., 1999; Waring et al.,
1999), but most discuss the methodological diculties
inherent in conducting and controlling large scale, sur-
vey based, studies and call for double blind analyses to
be performed.
One of the earliest clinical trials assessing the poten-
tial impact of estrogen on Alzheimer’s disease was a
small pilot study of seven women who had been diag-
nosed with senile dementia of the Alzheimer’s type
(Fillit et al., 1986). Low-dose estrogen therapy mod-
estly improved cognitive function and mood in some
of the women. The large prospective study of Hender-
son, Paganini-Hill and collaborators (Henderson et al.,
1994) also showed that estrogen not only protects
against the onset of Alzheimer’s disease, but also helps
to maintain the cognitive function of those women
who already have Alzheimer’s disease. The cognitive
function of women with Alzheimer’s disease who had
received estrogen replacement therapy was well below
non-demented control subjects, but better than the
cognitive function of those Alzheimer’s disease patients
not taking estrogen. Subsequent case-control (Resnick
et al., 1998) and retrospective (Costa et al., 1999) stu-
dies have confirmed that estrogen protects postmeno-
pausal women from cognitive deterioration.
Double-blind studies will be the key to confirming a
clinically significant role for estrogen in protection
from Alzheimer’s disease; the number of such studies
is still low, and study sizes are small, but the findings
support the use of estrogen to delay the onset of Alz-
heimer’s disease and slow its progression. In one
double-blind study of 12 women with mild to moder-
ate Alzheimer’s disease, estrogen (0.05 mg/day of 17b
estradiol, delivered via a skin patch), improved atten-
tion and verbal memory within the first week of treat-
ment, but the eects were temporary, and diminished
once estrogen treatment was stopped (Asthana et al.,
1999). It is of interest that there was a trend to an
inverse relationship between plasma levels of both
IGF-I and IGF-binding protein 3 and verbal memory,
given that IGF-I is generally neuroprotective (see
‘‘Neurotrophins’’, p. 45). Estrogen increased activation
of cortical regions involved in verbal memory tasks
during storage and retrieval of verbal material, without
altering verbal or nonverbal performance, in postme-
nopausal women given estrogen treatment (1.25 mg/
day, oral dose, 21 days, double-blind) and assessed
using functional magnetic resonance imaging.
The potential cellular mechanisms that may underlie
estrogen’s neuroprotective actions are discussed in Sec-
tion 3, but a specific series of genetic findings are
worth mentioning here with respect to estrogen and
Alzheimer’s disease susceptibility. First, there is an
apparent interaction between estrogen receptor, apoli-
poprotein E (ApoE) and deposition of amyloid in the
neuritic plaques that are one of the neuropathological
hallmarks of Alzheimer’s disease (Fig. 2). Some back-
ground regarding the role of ApoE and beta amyloid
is necessary here: ApoE is produced by astrocytes and
microglia (see also Section 3.2.3.1), is important to
membrane repair and synaptic plasticity (Teter et al.,
1999 and see Bales et al., 1999 for a discussion) and is
thought to reduce clearance of amyloid beta (Bales et
al., 1999). Amyloid beta is a component of neuritic
plaques that may itself be neurotoxic. The expression
of ApoE may in fact be necessary for production of
the abnormal amyloid deposits, since transgenic mice
that overexpress beta amyloid precursor protein and
are also ApoE(ÿ/ÿ) produce no amyloid deposits,
whereas amyloid deposits are frequent in ApoE(+/ÿ)
and ApoE(+/+) mice (Bales et al., 1999). There are
three allelic variants encoding three protein isoforms
of ApoE. Of these, the highest risk of Alzheimer’s dis-
ease, particularly the late-onset form, is found in indi-
viduals who are homozygous for the ApoE epsilon 4
allelle on chromosome 19 (Henderson et al., 1995). Es-
trogen may normally ward o damage due to ApoE
induced abnormalities in amyloid precursor protein
processing, as estrogen has been shown to reduce the
production of the neurotoxic, insoluble beta amyloid
(Jae et al., 1994; Chang et al., 1997; Xu et al., 1998a,
1998b). Exogenous estrogen reduces the risk of Alzhei-
Fig. 2. Possible actions of estradiol in Alzheimer’s disease. Estradiol
may aect beta-amyloid deposition by the regulation of beta-amyloid
metabolism and ApoE expression. The hormone may increase cogni-
tive function by enhancing cholinergic neurotransmission. Finally,
estradiol may influence aective disorders associated with Alzhei-
mer’s disease by acting on serotonin receptor signaling.
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mer’s disease in individuals who are either homozy-
gous or heterozygous for the ApoE epsilon 4 allele
(Tang et al., 1996).
Although it has been hypothesized that estrogen
protects against beta amyloid deposition via its anti-
oxidant properties (Mattson et al., 1997; Bonnefont et
al., 1998), nuclear receptor mediated mechanisms also
appear to be involved in estrogenic neuroprotection in
Alzheimer’s disease because estrogen receptor poly-
morphisms, as identified by restriction fragment length
polymorphism analysis as P or p alleles (PvuII- RFLP)
or X and x (Xba I-RFLP) are also associated with
dementia. The frequency of the P and X alleles for es-
trogen receptor were found to be higher in Alzheimer’s
disease patients and Parkinson’s disease patients with
dementia, but not in Parkinson’s patients without
dementia or in control subjects (Isoe-Wada et al.,
1999). One of the most important recent findings, po-
tentially of enormous predictive value, is a genetic in-
teraction between polymorphisms for both the
estrogen receptor and ApoE genes (Brandi et al., 1999;
Isoe-Wada et al., 1999). Brandi et al. (1999) calculated
that the frequency of late-onset of Alzheimer’s disease
was seven fold greater in those individuals that are
homozygous for ApoE epsilon 4 and ER-a PPXX.
Another important molecular association for estro-
gen in Alzheimer’s disease involves expression of cho-
line acetyltransferase (Fig. 2). Cholinergic neurons in
the basal forebrain degenerate in Alzheimer’s disease
patients (Whitehouse et al., 1981). Correlative studies
of choline acetyltransferase activity in biopsy speci-
mens results of neuropsychological tests have demon-
strated that the loss of choline acetyltranferase activity
is correlated with the loss of cognitive function (Baskin
et al., 1999). Estrogen upregulates choline acetyltrans-
ferase in the rat brain (Luine, 1985) although it is not
known whether this occurs in humans, nor is the po-
tential mechanism involved clear, since immunocyto-
chemical studies of the primate basal forebrain have
found that estrogen receptor alpha immunopositive
cells are rare and do not contain cholinergic markers
(Blurton-Jones et al., 1999).
Other neurotransmitter systems are also implicated
in the etiology of Alzheimer’s disease, and estrogen
may be protective through its eects on these systems
(Fig. 2). For example, estrogen normalizes neuroendo-
crine responses to a serotonergic agonist in postmeno-
pausal women (Halbreich et al., 1995) and may
decrease aective disorders via estrogen induced
decreases in the G proteins that couple serotonin
receptors to intracellular signaling molecules (Raap et
al., 2000) or via alterations in serotonin transporter ex-
pression (McQueen et al., 1997). Depression is one of
the early symptoms of Alzheimer’s disease; abnormal-
ities of serotonergic function have been proposed to be
causal in both disorders (e.g. Meltzer et al., 1998).
In conclusion, the etiology of Alzheimer’s disease is
clearly multifactorial, but for many of the factors, es-
trogen may provide protective value, and estrogen
receptor malfunction may increase risk. Considerable
support is therefore available for the use of estrogen
replacement therapy to decrease vulnerability to Alz-
heimer’s disease, and in those individuals who are
already diagnosed with Alzheimer’s disease, to main-
tain cognitive function (see note added in proof).
2.1.3. Schizophrenia
The overall lifetime risk for schizophrenia is not
dierent between men and women (reviewed in Linda-
mer et al., 1997; Seeman, 1997; Canuso et al., 1998;
Hafner et al., 1998). However, the age of onset, the
severity of symptoms, and the type of symptoms are
dierent in men and women and point to a protective
role for estrogen in schizophrenia. Schizophrenia gen-
erally occurs slightly later in women and, until meno-
pause, has a less severe course in women than in men.
Moreover, although the peak age of onset for schizo-
phrenia is generally late adolescence to early adulthood
in both men and women, a second cohort of women
develops schizophrenia at the onset of menopause, as
estrogen levels begin to fluctuate and decline (Linda-
mer et al., 1999). Numerous correlational studies show
that the severity of psychiatric disturbance decreases
with increasing estradiol levels during the menstrual
cycle and during pregnancy. Preliminary results from
limited clinical trials with hormone replacement
therapy provide further evidence that estrogen is pro-
tective, and decreases a specific subset of schizoid
symptoms.
Abnormalities of brain maturation may lead to
structural abnormalities that underlie schizophrenia,
and sex hormone exposure during development may
therefore contribute to the sex dierences in schizo-
phrenia (Gruzelier, 1994; Nopoulos et al., 1997). There
are conflicting results as to whether sex dierences
actually exist in the brain structural abnormalities as-
sociated with schizophrenia as would be expected if
sex hormone exposure during development contributes
to the greater vulnerability of the male brain. Two
carefully controlled, and similar magnetic resonance
imaging (MRI) studies demonstrate these conflicting
results. In the first, male and female hospitalized schi-
zophrenics had similar decreases in cortical gray mat-
ter and similar ventricular enlargement compared with
healthy, sex-matched controls (Lauriello et al., 1997).
In the second study, the cortical gray matter was
decreased and the ventricles were enlarged to a greater
extent in male schizophrenics compared with female
schizophrenics when each group was compared to its
healthy sex and age matched control group (Nopoulos
et al., 1997); these investigators emphasized that the
sex dierence is one of severity of the structural
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abnormality, rather than pattern. Dierent conclusions
have also been reached regarding sex dierences in the
extent of cognitive impairment in schizophrenic
patients, with some studies concluding that male
patients are more impaired than female patients (Gold-
stein et al., 1998) and others concluding that any sex
dierences in the degree of impairment are minimal
(Ho et al., 1998).
Modulation of dopaminergic function may underlie
the protective eects of estrogen. The dose of neuro-
leptic drugs required to treat women with schizo-
phrenia is lower than that for men, at least at the
younger ages (reviewed in Di Paolo, 1994 and in
Canuso et al., 1998). Estrogen may act essentially as
an endogenous neuroleptic since estrogen seems to
enhance the actions of dopamine antagonists in animal
models (Hafner et al., 1991). Preliminary results
suggest that dopamine receptor anity is lower in
some brain regions in women than in men (Pohjalai-
nen et al., 1998).
In addition to circulating estrogen, a genetic com-
ponent may also contribute to sex dierences in the
onset and course of schizophrenia (Hafner et al.,
1998). A case has been made by Gruzelier (1994) that
sex chromosomes may contribute to the observed
dierences in schizophrenia in men and women, par-
ticularly those sex dierences in the symptoms thought
to arise from abnormalities of brain lateralization.
Structural abnormalities in the temporoparietal region
and cognitive deficits have been observed in women
with Turner’s syndrome, who have either a karyotype
XO or a mosaic XO karyotype. The hormonal de-
ficiencies in both Turner’s syndrome groups are simi-
lar, but the cognitive and structural impairments of
the mosaic XO women are less severe than those of
full XO women. The structural abnormalities and pat-
terns of cognitive asymmetry observed in Turner
women and in Kleinefelter’s (XXY) men are consistent
with some of the abnormalities observed in schizo-
phrenia. Trinucleotide repeats confer some genetic risk
for schizophrenia, particularly the childhood onset
form of the disease, and are more common in males
(Burgess et al., 1998).
2.2. Experimental studies
2.2.1. In vitro evidence
For many years, it has been known that estradiol is
a factor that promotes viability and survival of neur-
ons in primary neuronal cultures. Estradiol is one of
the components that is added to serum-free defined
culture media for neuronal cultures (Faivre-Bauman et
al., 1981). Addition of 17b-estradiol to defined culture
media increases the viability, survival and dieren-
tiation of primary cultures from dierent neuronal
populations, including hypothalamic neurons (Chowen
et al., 1992; Duen˜as et al., 1996), amygdala neurons
(Arimatsu and Hatanaka, 1986), neocortical neurons
(Brinton et al., 1997) or hippocampal neurons (Sudo et
al., 1997). In addition, in vitro neuroprotective eects
of 17b-estradiol from cell death induced by a variety
of stressors are well documented (Table 1). The hor-
mone increases survival of cultured dorsal root
ganglion neurons deprived of nerve growth factor
(Patrone et al., 1999), primary mesencephalic cultures
exposed to glutamate, superoxide anions or hydrogen
peroxide (Sawada et al., 1998) and hippocampal cul-
tures exposed to NMDA (Weaver et al., 1997). Many
studies using primary cortical cultures have shown that
estradiol prevents neuronal death induced by dierent
stimuli such as iron (Vedder et al., 1999) glutamate
toxicity (Singer et al., 1996b; Zaulyanov et al., 1999),
AMPA toxicity (Zaulyanov et al., 1999), the pro-oxi-
dant hemoglobin (Regan and Guo, 1997), anoxia
(Zaulyanov et al., 1999), cytochrome oxidase inhibitor
sodium azide, kainate or NMDA (Regan and Guo,
1997). Other studies have used neuronal cell lines to
demonstrate the neuroprotective eects of estradiol.
For instance, 17b estradiol protects NT2 neurons,
PC12 cells and mouse neuroblastoma (Neuro 2a) cells
from H2O2 or glutamate induced cell death (Singer et
al., 1998; Bonnefont et al., 1998), SK-N-SH human
neuroblastoma cells from serum deprivation (Green et
al., 1997), hippocampal HT 22 cells from lipid peroxi-
dation (Vedder et al., 1999) and B 103 cells (Mook-
Jung et al., 1997), PC12 cells and Neuro 2a cells (Bon-
nefont et al., 1998) from neurotoxic eects of beta
amyloid. This long, but not exhaustive, list of studies
reveals that the neuroprotective eects of estradiol
have recently received considerable attention. These in
vitro studies have provided important insights into the
possible mechanisms involved in the in vivo neuropro-
tective eects of estrogen that will be discussed below.
Table 1
Summary of experimental lesion models in which estradiol has been
shown to be neuroprotective
Estradiol neuroprotection in experimental lesion models
In vitro (Section 2.2.1) In vivo (Section 2.2.2)
Anoxia Ischemia
Serum deprivation Neurotoxins
Oxidative stress MPTP
Hemoglobin 6-Hydroxydopamine kainic acid
Iron Axotomy
Hydrogen peroxyde
Sodium azide
Excitatory aminoacids
Glutamate
Kainate
NMDA
b-Amyloid protein
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2.2.2. In vivo evidence
In addition to the extensive evidence for neuropro-
tective eects of estradiol in vitro, there is now abun-
dant evidence for neuroprotection by the hormone in
dierent experimental models in vivo (Table 1). In
agreement with clinical findings, several animal studies
have shown that estrogen improves memory perform-
ance in females. Estrogen replacement improves work-
ing memory in ovariectomized rats (Simpkins et al.,
1997a; Bimonte and Denenberg, 1999; Fader et al.,
1999) but does not aect reference memory perform-
ance (Fader et al., 1999). In ovariectomized mice, tonic
estrogen replacement therapy improves two dierent
types of memory processes that depend on striatal and
hippocampal memory systems (Rissanen et al., 1999).
Estrogen treatment has been shown to improve mem-
ory performance in male rodents as well. Estradiol
treatment of male rats partially compensates for the
learning deficits and deterioration of memory induced
by the intracerebroventricular administration of strep-
tozotocin (Lannert et al., 1998). These findings suggest
that estrogen may have a general enhancing eect on
neural activity and may be involved in the normal
maintenance of neural function. Therefore, the decline
in estrogen levels that occurs with age may be the
cause of the increased rate of age-related cognitive
impairments in female rodents compared to males
(Markowska, 1999; Frick et al., 2000). The decrease in
estrogen levels with age in females may increase the
risk of neurodegenerative disorders since the hormone
has been shown to protect neurons in vivo from dier-
ent lesion paradigms.
Experimental forebrain ischemia has been one of the
models used to test the neuroprotective eect of estra-
diol in vivo. The protective eects of estrogen in this
model have been documented in rats (Simpkins et al.,
1997b; Dubal et al., 1998; Pelligrino et al., 1998;
Zhang et al., 1998; Wang et al., 1999; Rusa et al.,
1999), mice (Culmsee et al., 1999) and gerbils (Sudo et
al., 1997; Chen et al., 1998). Simpkins et al. (1997b)
have shown that pretreatment with 17b-estradiol
reduces animal mortality and ischemic area in ovari-
ectomized rats after middle cerebral artery occlusion.
Interestingly, the isomer 17a was able to reduce mor-
tality and to reduce the ischemic area as well. Both
systemic and intracerebral administration of 17b-estra-
diol were protective in this model. In the study of
Dubal et al. (1998), systemic estradiol pretreatment sig-
nificantly reduced overall infarct volume compared
with oil injected controls. Sudo et al. (1997) tested the
eect of estradiol administered into the lateral cerebral
ventricle. These authors have shown that 17b-estradiol
infused into the lateral cerebral ventricle prevents
ischemia-induced learning disability and neuronal loss
at early stages after transient forebrain ischemia in ger-
bils (Sudo et al., 1997). Chen et al. (1998) have also
found a neuroprotective eect of 17b-estradiol on CA1
hippocampal cells after ischemia in gerbils. Further-
more, 17b-estradiol decreases the expression of beta-
amyloid precursor protein mRNA following focal
ischemia in ovariectomized female rats (Shi et al.,
1998).
Another experimental model of great interest is
injury of the nigrostriatal system. Estrogen has neuro-
protective properties against 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP)-induced neurotoxicity in
the nigrostriatal dopaminergic system. Estradiol treat-
ment prevents reductions in dopamine concentrations
in the striatum of ovariectomized mice (Dluzen et al.,
1996a, 1996b; Dluzen, 1997, 2000; Callier et al., 2000).
Furthermore, 17b-estradiol reduces the dyskinetic
eect of MPTP in cynomolgus monkeys, while 17a-
estradiol is ineective (Gomez-Mancilla and Bedard,
1992). Basal forebrain cholinergic neurons may also be
protected by estradiol, since Rabbani et al. (1997)
found that administration of 17b estradiol to ovari-
ectomized rats attenuated the decrease of choline acet-
yltransferase immunoreactive neurons in the medial
septum after fimbria lesion-induced degeneration.
The neuroprotective eect of estradiol on the hilus
of the dentate gyrus has been investigated after sys-
temic administration of kainic acid, a widely used ex-
perimental model of epilepsy and neurodegeneration.
Kainic acid treatment results in the appearance of
chronic, spontaneous, recurrent seizures and neurode-
generative changes in the dentate gyrus, including loss
of somatostatinergic interneurons in the hilus. Systemic
administration of a low dose of kainic acid (7 mg/kg
b.w.) results in mild behavioral symptoms and a loss
of no more than 25–40% of Nissl-stained hilar neur-
ons. Administration of 17b-estradiol to ovariectomized
rats is able to prevent this partial hilar neuronal loss
(Azcoitia et al., 1998). Of critical importance with
regard to the normal neuroprotective eects of estro-
gen, the eect of kainic acid on hilar neurons in intact
female rats is dierent depending on the day of the
estrous cycle on which the neurotoxin is injected. No
significant neuronal loss is observed when kainic acid
is injected on the morning of estrus. In contrast, there
is a significant loss of hilar neurons when kainic acid is
injected in the morning of proestrus as well as when it
is injected into ovariectomized rats (Azcoitia et al.,
1999a). These findings demonstrate that the natural
fluctuation of ovarian hormones during the estrous
cycle may influence the vulnerability of hilar neurons
to excitotoxicity.
The possible neuroprotective eect of estrogen has
been tested in male rats as well. Estradiol treatment
results in an increase in the rate of regeneration of
axotomized facial motoneurons of male hamsters, an
eect also induced by testosterone and by the non aro-
matizable androgen dihydrotestosterone (Tanzer and
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Jones, 1997). Toung et al. (1998) have found that
either acute or chronic administration of 17b-estradiol
protects the male rat brain after experimental stroke
using 2 h of reversible middle cerebral artery occlusion.
Cortical and caudate infarct volumes are reduced by
acute and chronic hormonal treatments. Toung et al.
(1998) and Kujawa and Jones (1991) also studied the
eect of castration on neural response to injury. Cas-
tration did not alter ischemic outcome whereas estro-
gen replacement reduced infarct volume in castrated
animals. Similarly, the rate of regeneration following
facial nerve axotomy was not dierent in intact vs.
castrated male hamsters (Kujawa and Jones, 1991).
Both studies suggested that circulating testosterone
levels are insucient to supply prohormone to provide
neuroprotective levels of estrogen in vivo. Estrogen
also has neuroprotective properties against MPTP-
induced neurotoxicity in the nigrostriatal dopaminergic
system of castrated males, preventing reductions in
corpus striatum dopamine concentrations (Dluzen et
al., 1996a, 1996b). However, the interpretation of the
neuroprotective eects of estrogen in male animals is
complicated by the possible influence of androgens.
Clinical data show that women recover better than
men after traumatic brain injury (Groswasser et al.,
1998). In agreement with this observation, and with
those commented on in Section 2.1.1 in several exper-
imental neural lesion models male animals are more
vulnerable than female animals. For instance, female
rats have better stroke outcomes after vascular occlu-
sion than males (Li et al., 1996; Alkayed et al., 1998;
Zhang et al., 1998), while male rats show stronger
memory deficits after entorhinal cortex lesions than
females (Roof et al., 1993a). Sex dierences have been
also observed in striatal dopaminergic neurotoxicity in
mice (Miller et al., 1998). Two neurotoxicants tested,
MPTP and methamphetamine (METH), resulted in a
greater dopamine depletion in males than in females
(Yu and Wagner, 1994; Miller et al., 1998). However,
in a study in which the susceptibility of the cholinergic
septo-hippocampal pathway to the neurotoxic eect of
ethylcholine aziridinium (AF64A) was investigated in
the rat, Hortnagl et al. (1993) found that adult female
rats in general, and particularly females on proestrus,
were more susceptible to the neurotoxic action of sub-
maximal doses of AF64A than age-matched male rats.
Sex dierences in outcome after dierent forms of
brain lesions may be due in part to estrogen, pro-
gesterone or testosterone. Neuroprotective eects of
progesterone will not be covered in depth in this
review, except to mention that several studies have
shown that progesterone may reduce cerebral damage
after dierent forms of insults (Stein and Fulop, 1998).
For instance, progesterone facilitates cognitive recov-
ery, reduces secondary neuronal loss and protects
against lipid peroxidation following traumatic brain
injury in rats (Roof et al., 1993b, 1994, 1997; Asbury
et al., 1998) and reduces neuronal loss in the cat hip-
pocampus after acute cerebral ischemia (Gonzalez-
Vidal et al., 1998). Sex dierences in the response to
brain injury may also be the consequence of a dama-
ging eect of testosterone. While testosterone is a sur-
vival factor for axotomized motoneurons and
promotes motor axon regeneration (Yu, 1989; Jones,
1993; Kujawa et al., 1993; Perez and Kelly, 1996,
1997; Kinderman et al., 1998), the hormone may have
a negative eect for other injured neuronal popu-
lations. For instance, testosterone increases the lesion
size induced by middle cerebral artery occlusion in
castrated male rats, while estradiol treatment reduces
the ischemic area (Hawk et al., 1998). Nishino et al.
(1998) have used systemic intoxication with 3-nitropro-
pionic acid, a succinate dehydrogenase inhibitor, to
induce selective histological lesions in the striatum.
These lesions are associated with motor symptoms and
are highly sex-dependent. Males are more susceptible
than females. Gonadectomy has little eect on males
but enhances the vulnerability of females to the sub-
stance. Furthermore, testosterone increases the vulner-
ability while estrogen replacement suppresses the
vulnerability in ovariectomized rats (Nishino et al.,
1998).
The deleterious eect of testosterone in some exper-
imental models of brain injury may be secondary to its
conversion to dihydrotestosterone and its action on
androgen receptors. However, it is important to con-
sider the possibility that the negative eect of testoster-
one may be the consequence of its conversion to
estradiol by local aromatase activity. It is well known
that high levels of estradiol may be neurotoxic for
some hypothalamic neurons (Brawer et al., 1978; Des-
jardins et al., 1995), and the idea cannot be excluded
that high local levels of estrogen may be neurotoxic
for other neuronal populations as well. This would
mean that high local levels of estrogen may be deleter-
ious while low local levels of estrogen may provide
neuroprotection. Therefore, it is important to deter-
mine the concentration of estradiol that may exert a
neuroprotective eect in vivo.
Several studies have assessed whether the neuropro-
tective eects of estrogen in dierent lesion paradigms
are dose-dependent. For example, the eect of estra-
diol in preventing ischemic damage is dose-dependent.
When infused at a dose of 0.25 mg/day, estradiol
decreased ischemic damage in gerbils, whereas a dose
of 1.25 mg/day was ineective and even increased mor-
tality of experimental animals (Sudo et al., 1997).
Dierent results have been obtained by Chen et al.
(1998). According to these authors, high doses of 17b-
estradiol improve the histological outcome after transi-
ent forebrain ischemia in hippocampal CA1 pyramidal
cells of gerbils, whereas low doses of estradiol do not
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have any protective eect. In rats, chronic low-dose
estradiol treatment (0.1 mg/kg per day) has a beneficial
eect on cortical cerebral blood flow during forebrain
ischemia. However, the benefit is lost with a dose of
0.5 mg/kg per day or with higher doses (Pelligrino et
al., 1998). Dubal et al. (1998) have found neuroprotec-
tive eects of low (10 pg/ml in plasma) and high (100
pg/ml in plasma) estradiol levels in the rat cerebral
cortex after ischemia. In another study, long term
treatment with 17b-estradiol implants of 25 mg (result-
ing in 20 pg/ml in plasma) reduces stroke injury in
ovariectomized females while implants of 100 mg (46
pg/ml in plasma) do not (Rusa et al., 1999). These stu-
dies show some discrepancies concerning the optimal
dose of estradiol needed to obtain a neuroprotective
eect in vivo. This may be in part because dierent
brain areas require dierent optimal hormone concen-
trations. The severity of the lesion and the route of ad-
ministration may also be an important determinant in
the hormone concentration required to counterbalance
the damage. In spite of the discrepancies, most studies
show a neuroprotective eect at low estradiol doses.
This finding is relevant to the mechanism of action, as
discussed below.
3. Mechanisms of neuroprotection by estradiol
3.1. Peripheral versus local eects
The possible neuroprotective mechanisms of estra-
diol may be divided into two basic groups: local and
peripheral, local eects being those exerted directly in
the nervous system and peripheral eects being those
exerted in other tissues, such as the systemic regulation
of metabolism and the cardiovascular system. Hormo-
nal eects on the cardiovascular system may facilitate
brain irrigation and therefore may protect neurons and
glia from ischemia. Peripheral metabolic and cardio-
vascular eects of the hormone will not be considered
in this review. Among the local eects, it is important
to distinguish those mediated by the activation of es-
trogen receptors and those that are not dependent on
the actions of estrogen receptors. Furthermore, the
local eects of estradiol may be divided into those
exerted on neurons and those exerted on glial cells or
other cellular elements of the nervous system. These
dierent local eects of estrogen will be considered in
the following sections.
3.2. Local eects
3.2.1. Mechanisms independent of the transcriptional
activation by estrogen receptors
Among the local hormonal eects, there is a strong
line of evidence supporting mechanisms independent of
estrogen receptor activation. Some in vitro studies
have shown that high, non-physiological doses of
estradiol are neuroprotective while low doses of estra-
diol, optimal to induce estrogen receptor-mediated
gene transcription, are not. For instance, 133 nM 17b-
or 17a-estradiol but not 1.3 nM 17b-estradiol protect
primary rat cortical neuronal cultures from anoxia-
reoxygenation, glutamate, or AMPA toxicity (Zaulya-
nov et al., 1999). Furthermore, protective eects of
estradiol have been documented in neuronal cell lines
lacking functional estrogen receptors or in the presence
of estrogen receptor antagonists. Both 17a and 17b-
estradiol provide protection of SK-N-SH human neu-
roblastoma cells from serum deprivation and the neu-
roprotective eect was only partially reversed by the
estrogen receptor antagonist tamoxifen. This finding
suggests that estrogen may have neuroprotective eects
that are not mediated by estrogen receptor signaling
(Green et al., 1997), although another possibility is
that tamoxifen exerted partial agonist activity in these
cells. A neuroprotective eect of estradiol independent
of estrogen receptors has been demonstrated in the
HT-22 murine neuronal cell line. 17b estradiol and 17a
estradiol protect HT-22 cells from beta-amyloid pep-
tide toxicity, in spite of the fact that these cells lack
functional estrogen receptors (Green et al., 1998).
Neuroprotection independent of estrogen receptors
has been observed in primary neuronal cultures as
well. The estrogen receptor antagonist, tamoxifen,
does not interfere with the neuroprotective eects of
17b-estradiol against NMDA-induced neuronal death
in rat hippocampal cultures (Weaver et al., 1997). Fur-
thermore, neither estrogen receptor antagonists nor
protein synthesis inhibitors block estrogen-induced
protection against glutamate neurotoxicity in mesence-
phalic cultures (Sawada et al., 1998). In addition, es-
trogen receptor antagonists do not block the protective
eects of estradiol against pro-oxidants in rodent and
chick neuronal cultures (Behl et al., 1995, 1997; Regan
and Guo, 1997; Culmsee et al., 1999; Moosmann and
Behl, 1999).
One of the most popular views to explain the neuro-
protective eects of the hormone is related to the en-
dogenous antioxidant capacity of the estradiol
molecule (Fig. 3). It is very well documented that
estradiol has antioxidant properties and suppresses the
oxidative stress in neurons and neuronal cell lines
induced by hydrogen peroxide, superoxide anions and
other pro-oxidants (Behl, 1999; Behl et al., 1995, 1997;
Mattson et al., 1997; Bonnefont et al., 1998; Sawada et
al., 1998; Behl and Holsboer, 1999; Calderon et al.,
1999; Culmsee et al., 1999; Kruman et al., 1999; Moos-
mann and Behl, 1999; Behl and Manthey, 2000). Both
17a and 17b estradiol have similar antioxidant eects
(Behl et al., 1995, 1997; Calderon et al., 1999; Bonne-
font et al., 1998).
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Supraphysiologic concentrations of estradiol have a
clear antioxidant eect in vitro. For instance, 17b-
estradiol, 17a-estradiol and some estradiol derivatives
can prevent intracellular peroxide accumulation and
degeneration of cultured neurons and clonal hippo-
campal cells. The antioxidant activity of estrogens is
observed at very high concentrations (10ÿ5 M), is
dependent on the presence of the hydroxyl group in
the C3 position on the A ring of the steroid molecule
and is independent of an activation of the estrogen
receptors (Behl et al., 1995, 1997; Culmsee et al., 1999;
Moosmann and Behl, 1999; Behl and Manthey, 2000).
A similar finding has been reported by Regan and
Guo (1997), showing that 17b-estradiol at a dose of 10
mM results in a complete prevention of neuronal loss
in murine cortical cultures due to prolonged exposure
to the pro-oxidant hemoglobin. Most of this eect per-
sisted despite concomitant treatment with the anties-
trogen ICI 182, 780 or the protein synthesis inhibitor
cycloheximide (Regan and Guo, 1997).
Lipid peroxidation of membrane and fatty acids rep-
resents an important endpoint of pro-oxidative cell
damage. Keller et al. (1997) and Vedder et al. (1999)
have used iron, one of the most powerful initiators
and propagators of lipid peroxidation, to determine
the role of estradiol on lipid peroxidation. These
authors found that 17b-estradiol decreases iron-
induced lipid peroxidation in rat brain homogenates
(Vedder et al., 1999), rat cortical synaptosomes (Keller
et al., 1997), hippocampal HT 22 cells and primary
neocortical cultures (Vedder et al., 1999). However, it
is unlikely that this mechanism will be relevant clini-
cally for the neuroprotective eects of estradiol, since
very high concentrations of the hormone are necessary
to reduce lipid peroxidation (Vedder et al., 1999).
In conclusion, it is clear that estradiol has antioxi-
dant properties and may protect neurons from oxi-
dative stress. However, these eects are observed with
high supraphysiologic concentrations of the hormone
and their relevance to the neuroprotective eects of
estradiol in vivo is questionable, particularly in a clini-
cal sense. It should be noted, however, that it is
unknown what the local concentrations of the hor-
mone may be in a focal injured area in the brain. The
recent discovery that aromatase expression is induced
de novo in reactive astrocytes in injured brain areas
(Garcia-Segura et al., 1999a) opens the possibility that
injury induced increases in aromatase synthesis, and
therefore increased local estrogen formation, may
result in high local estrogen levels in the proximity of
damaged neurons.
In addition to anti-oxidant eects, estradiol may use
other possible neuroprotective mechanisms that are
independent of nuclear estrogen receptor activation
(Fig. 3). Estradiol may interact with estrogen binding
sites in the plasma membrane (Ramirez and Zheng,
1996) and may have many dierent rapid eects on
neuronal excitability (Moss and Gu, 1999) and neur-
onal transmission (Bicknell, 1998). In rat hippocampal
cultures estradiol may protect neurons from excitotoxi-
city by having direct membrane actions (Weaver et al.,
1997). The neuroprotective eect of 17b-estradiol is
dose-dependent, with an EC50 of about 7 mM. In this
model, 17a-estradiol does not reduce NMDA-induced
neuronal death, indicating that the neuroprotective
eect of estradiol is stereospecific. However, tamoxifen
does not interfere with the neuroprotective eect,
suggesting that estrogen receptors are not required for
neuroprotection (Weaver et al., 1997). Since both a-
and b-estradiol should have similar abilities to sca-
venge free radicals and since 17b-estradiol rapidly and
reversibly inhibits the NMDA-induced current of cul-
tured neurons, Weaver et al. (1997) conclude that the
neuroprotective eect of the hormone may be a conse-
quence of direct inhibition of NMDA receptor func-
tion. The neuroprotective eects of the hormone may
be in part related to the modulation of neurotransmit-
ters. For instance, estradiol may protect the nigrostria-
tal system by the regulation of dopamine release and
via the inhibition of dopamine uptake by decreasing
the anity of the transporter for dopamine (Disshon
and Dluzen, 1997; Disshon et al., 1998; Dluzen, 2000).
Neuroprotective eects that involve hormonal acti-
vation of intracellular signaling pathways via G pro-
teins (Moss and Gu, 1999; Raap et al., 2000),
extracellularly regulated kinases (see Section 3.2.3.3),
phosphorylation of the cAMP response element bind-
ing protein (Zhou et al., 1996; Murphy and Segal,
1997; Panickar et al., 1997; Watters and Dorsa, 1998;
Fig. 3. Summary of mechanisms independent of the activation of
nuclear estrogen receptors that may be involved in estrogen-induced
neuroprotection. 1, Estrogen may act on unidentified membrane sites
and activate membrane associated signaling cascades that result in
neuroprotection. The membrane-associated signaling may involve
modifications in protein phosphorylation and modifications in the
levels of intracellular signals such as cAMP and calcium. Alterna-
tively, membrane related signaling cascades may result from the in-
teraction of estradiol with putative membrane estrogen receptors (see
Fig. 4). 2, Estradiol may act as an antioxidant. 3, Estradiol may
aect neurotransmitter receptors, such as glutamate receptors, and
regulate ionotropic and metabotropic activity.
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Walton and Dragunow, 2000), and alterations in intra-
cellular calcium levels (Beyer and Raab, 1998; Pozzo-
Miller et al., 1999) should still be explored in detail.
3.2.2. Mechanisms mediated by the activation of
estrogen receptors and gene transcription
3.2.2.1. Estrogen receptor mediated transcription in the
nervous system. Many, though not all, of the physio-
logical eects of estrogen are mediated through bind-
ing to estrogen receptor (ER) proteins. Like other
members of the steroid receptor superfamily, estrogen
receptors are ligand-activated transcription factors that
are expressed in specific regions within target areas of
the nervous system and other estrogen-sensitive
organs. Until 1996, it was thought that only one estro-
gen receptor existed, but in that year and the next, two
surprising discoveries indicated the presence of more
than one estrogen receptor and greatly stimulated the
field of estrogen receptor research. The first surprise
came from accumulated evidence that, contrary to ex-
pectations, disruption of the estrogen receptor gene in
mice did not disrupt all estrogen dependent functions;
in the estrogen receptor knock out mice, residual levels
of estrogen binding were present in several brain
region and estrogen induced expression of progester-
one receptor, an estrogen-dependent gene (Shughrue et
al., 1997a, 1997c). This research team concluded that,
since the conventional ER had been disrupted, a var-
iant form of ER might be present.
The second surprise discovery, also announced in
the spring of 1996, was that a new estrogen receptor
protein had been cloned (Kuiper et al., 1996). With
this finding, the conventionally defined ER was desig-
nated estrogen receptor-a (ER-a), and the new one
was named ER-b. ER-b mRNA was rapidly identified
in numerous tissues, including the adult rat brain
where it was found in a distribution that overlaps that
of ER-a in some regions, but in other regions is quite
distinct, as discussed below. Multiple splice variants of
ER-b have been identified, adding another layer of
complexity to estrogen signal transduction (Petersen et
al., 1998; Hanstein et al., 1999). Of these splice var-
iants, ER-b1 is probably the only variant with su-
cient abundance and anity for estrogenic ligands to
exert important neural eects, although alterations in
splicing following neural damage cannot yet be ruled
out.
ER-a and ER-b share a structure that is similar to
that of all members of the nuclear hormone receptor
superfamily, and have highly homologous amino acid
sequences in some domains, particularly the DNA-
binding domain (Kuiper et al., 1996). Both have an ac-
tivation function domain in the amino terminus (AF-
1), a central DNA binding domain and a carboxy ter-
minus ligand binding domain, in which a second acti-
vation function (AF-2) resides. In vivo, estrogen
receptors exist in association as part of an oligomeric
protein complex that includes heat shock proteins and
immunophilins (Tsai and O’Malley, 1994). Upon bind-
ing to ligand, or following ligand-independent acti-
vation, estrogen receptors partially dissociate from this
oligomer, and estrogen receptors form homo- and het-
ero-dimers (Cowley et al., 1997; Pettersson et al., 1997)
that then bind to specific DNA sequences in target
genes. The specific DNA sequences, termed estrogen
response elements (EREs), are located in the promoter
region of estrogen responsive genes, and influence the
rate of gene transcription. Although characteristically
formed by inverted repeat sequences, functional ana-
lyses of individual genes are necessary to identify
EREs, because some estrogen response elements are
formed by half-palindromic ERE-like motifs with a
few mismatched base pairs (Donaghue et al., 1999;
Aumais et al., 1996; Kato et al., 1992). For instance,
promoter analyses have failed to identify perfect palin-
dromic EREs in the promoter region of the mamma-
lian ER-a gene (e.g. Donaghue et al., 1999; but see Le
Drean et al., 1995 in trout and Lee et al., 1995 in
frog), but half-ERE sites with one or a few mis-
matched base pairs are frequent, and may allow a
functional estrogen response. Putative EREs have been
identified in the promoter region of multiple genes that
are both essential to normal brain function and impli-
cated in brain disorders. Among these are the genes
encoding choline acetyltransferase (Miller et al., 1999),
the GABA transporter GAT-1 (Herbison et al., 1995),
a1a-adrenergic receptor (Lee et al., 1998), preproenke-
phalin (Zhu and Pfa, 1995), oxytocin (Adan et al.,
1993; Bale and Dorsa, 1997; Young et al., 1996), so-
matostatin (Xu et al., 1998a, Xu et al., 1998b), galanin
(Kofler et al., 1995; Corness et al., 1997), glial fibrillary
acidic protein (Stone et al., 1998b), brain-derived neu-
rotrophic factor (Sohrabji, et al., 1995), transforming
growth factor-alpha (El-Ashry et al., 1996), Fos (Weisz
and Rosales, 1990), Myc (Dubik and Shiu, 1992),
cyclin D1 (Sabbah et al., 1999) and Bcl-2 (Teixeira et
al., 1995).
The finding of a new estrogen receptor subtype gen-
erated intense interest because of the underlying
assumption that ER-a and ER-b would regulate dier-
ent target genes. Tissue specific expression and dier-
ences in the ratio and regulation of these two receptor
subtypes may contribute to the wide diversity of tissue
specific eects that occur in response to estrogen. The
genes that are exclusively regulated by ER-a versus -b
are unknown, in part because attempts to identify
unique ligands and antagonists have not yet led to
huge success. However, in addition to dierences in
the distribution of the two receptor subtypes, dier-
ences in the impact on the nervous system of ER-a
versus ER-b knockouts have already been identified;
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for example, ER-a knockout mice are virtually incap-
able of masculine reproductive behaviors (Ogawa et
al., 1997, 1998) and ER-a knockout females did not
display sexual receptivity (Rissman et al., 1997),
whereas reproductive behavior in ER-b knockouts
appears to be essentially normal (Ogawa et al., 1999).
It is not yet known whether the neuroprotective eects
are mediated through only one or both of these recep-
tor subtypes or their splice variants.
During the last five years, a wealth of new infor-
mation has accumulated on the mechanisms underlying
estrogen receptor dependent gene activation. For
example, it is now known that estrogen receptors inter-
act with the basal transcriptional machinery through
complex interactions with other transcription factors
and with identified coactivators and adapter proteins
(reviewed in Horwitz et al., 1996) which also remodel
chromatin. These coactivators and adapter proteins
may be present in limiting amounts and may impart
transcriptional specificity. Sequences within coactivator
proteins, such as the nuclear receptor interaction box,
may also stabilize the binding of agonists to ER, eec-
tively increasing the level of functional estrogen and
modulating temporal aspects of estrogen action by
profoundly slowing (over 50-fold in cell free dis-
sociation assays) the dissociation rate of estrogen ago-
nists (Gee et al., 1999). The eects of specific peptide
sequences within these coactivators appear to interact
with some ER subtype specificity. Another coactivator
that may be important to estrogen action is the andro-
gen receptor associated protein designated ARA-70
(Yeh et al., 1998). ARA-70 not only increases the e-
cacy of androgen induced AR transcriptional activity,
but also allows estradiol to act as a ligand for andro-
gen receptors, increasing AR transcriptional activity
by up to 30-fold. Androgen receptors are expressed at
moderate to high levels in many cells in regions that
have been shown to benefit from estrogen’s neuropro-
tective actions, including the hippocampal formation
(Kerr et al., 1995), and the cerebral cortex (Simerly,
1990; Puy et al., 1995; Finley and Kritzer, 1999; McA-
bee and DonCarlos, 1998). Thus, some of the neuro-
protective actions of estrogen may be mediated via
estrogen’s binding to androgen receptors, although
whether ARA-70 is expressed in the nervous system
has not been confirmed. In addition to interacting with
estrogen response elements and possibly androgen re-
sponse elements, estrogen receptors are able to aect
transcriptional responses to other transcription factors,
such as Jun and Fos at AP-1 sites (Paech et al., 1997),
perhaps through protein-protein interactions that do
not rely on binding to an estrogen response element
(Webb et al., 1999). Results from molecular studies,
largely carried out in cell culture, will need to be veri-
fied in vivo, and in specific tissues, to determine
whether phenomena such as heterodimerization, cross-
interference of steroid receptors, and ERE independent
transactivation constitute important, physiologically
relevant mechanisms for estrogen signal transduction.
It will be of critical interest to determine which specific
coactivators or adapter proteins are expressed in the
nervous system and whether their expression and regu-
lation can be manipulated to enhance the neuroprotec-
tive eects of estrogen.
In addition to estrogen receptors acting as transcrip-
tion factors within nuclei, there is increasing and very
exciting evidence that estrogen receptors may mediate
the eects of estrogen via interaction with intracellular
signaling cascades (e.g. Lagrange et al., 1996, 1997;
Mermelstein, 1996; Singer et al., 1999; Singh et al.,
1999; Toran-Allerand, 1996; Kelly et al., 1999; see also
Section 3.2.3.3). Kelly, Ronnekliev and colleagues
(Lagrange et al., 1996, 1997; Kelly et al., 1999) have
established that estradiol can uncouple GABA-B and
mu-opioid receptors from potassium channels via acti-
vation of protein kinase A and C. Estrogen activates
mitogen-activated protein kinase (MAPK) and B-ras
(Singh et al., 1999), an eect that is involved in the
ability of estrogen to protect against glutamate
induced nerve cell death (Singer et al., 1999). G pro-
teins are also activated by estrogen in the striatum, an
area where membrane receptors have been hypoth-
esized to exist (Mermelstein et al., 1996; Becker, 1999
and see discussion below). All of these eects are rapid
and depend on the presence of estrogen receptor (or a
putative membrane receptor, in the case of the stria-
tum) but not on protein synthesis. These very exciting
findings of convergent pathways for estrogen receptor
Fig. 4. Summary of mechanisms of neuroprotection dependent on
the activation of estrogen receptors. Estradiol may bind to putative
estrogen receptors in the plasma membrane and activate membrane
associated signaling cascades. Alternatively, these signaling cascades
may be activated by acting on other unidentified membrane binding
sites (see Fig. 3). Estradiol may also act on conventional nuclear
receptors and regulate transcription of growth factor receptors, cyto-
skeletal proteins and antiapoptotic molecules, all of them resulting in
neuroprotection.
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modulation of cellular function have led to hypotheses
that the trophic eects of estrogen and estrogen recep-
tors involve complementary activation of transcription,
via estrogen receptor binding to estrogen response el-
ements, and estrogen receptor activation of signal
transduction pathways, perhaps via ligand-induced
release of constituents of the multimeric complex of
the estrogen receptor complex (see Toran-Allerand et
al., 1999 for a discussion), or via a membrane receptor
(Fig. 4).
A putative membrane receptor for estrogen has been
postulated for many years, (Ramirez and Zheng, 1996;
Becker, 1999), supported primarily by electophysiologi-
cal studies that demonstrated rapid eects of estrogen
on the activity of neurons in a variety of brain regions
(Foy et al., 1984; Smith et al., 1987, 1988; Kelly et al.,
1999; and see reviews in Moss et al., 1997; Bicknell
1998; and Becker, 1999) and binding studies showing
that estrogen binds to membrane fractions (Zheng and
Ramirez, 1997). In addition, immunoreactivity for the
classically defined nuclear estrogen receptors (discussed
below) has been identified in axon terminals (Blaustein
et al., 1992; Wagner et al., 1998). It is now thought
that at least one class of these putative membrane es-
trogen receptors is synthesized from the same tran-
scripts as the nuclear receptors and has a similar
anity for ligand (Razandi et al., 1999). These mem-
brane estrogen receptors appear to function in estro-
gen signal transduction, in that estrogen rapidly
activated G proteins, increased inositol phosphate syn-
thesis and increased adenylate cyclase activity in either
ER-a or ER-b transfected Chinese hamster ovary cells
(CHO cells). However, when either ER-a or ER-b was
overexpressed in CHO cells, over 95% of ER-a and -b
receptor protein was found in nuclear cell fractions,
whereas less than 3% was found in membrane frac-
tions (Razandi et al., 1999). Whether the putative
membrane estrogen receptors in the brain are derived
from alternate post-translational processing of the clas-
sical nuclear estrogen receptor genes is not yet known.
However, it is clear that rapid eects of estrogen, alter-
ing phosphorylation events or calcium release, could
importantly modify the transcriptional regulatory
eects of estrogen receptors, and may account for
some of the ‘‘non-receptor’’ mediated eects described
above (see Section 3.2.1).
3.2.2.2. Estrogen receptor distribution in the central ner-
vous system. Steroid autoradiography, immunocyto-
chemistry and in situ hybridization have been used to
localize estrogen receptors in the nervous system. Each
method provides a unique perspective on estrogen
receptor biosynthesis and activity. Of primary import-
ance is that the patterns of estrogen receptor ex-
pression found with each method match very closely,
with some occasional exceptions (Toran-Allerand et
al., 1992b). Extensive steroid autoradiographic studies
have pointed to the remarkable evolutionary conserva-
tion of the regional distribution of estrogen receptor
expression in the nervous system (Morrell and Pfa,
1983).
The distributions of ER-a and ER-b largely overlap
(Li et al., 1997; Shughrue et al., 1997b, 1997d; the
reader is referred to these articles for detailed descrip-
tions of the precise distribution of ER-a and -b expres-
sing cells in the brain), and the two receptor subtypes
are expressed in the same cells in some regions (Shugh-
rue et al., 1998). The regions with the highest densities
of cells expressing estrogen receptors are found in the
forebrain, in the preoptic area, hypothalamus and
amygdala, particularly in subdivisions of these regions
that are vital to reproductive function (Pfa and Kei-
ner, 1973; Warembourg et al., 1989; DonCarlos et al.,
1991), and in the peripheral nervous system, in the
dorsal root ganglion (Sohrabji et al., 1994a; Taleghany
et al., 1999). Estrogen receptor beta mRNA expression
is higher than ER-a expression in the paraventricular
nucleus and much higher in the medial tuberal nucleus,
whereas ER-a mRNA expression is much greater than
ER-b expression in the ventromedial and arcuate
nuclei of the hypothalamus.
The proportion of total cells that are estrogen tar-
gets in a brain region, and the amount of binding per
cell, as determined using steroid autoradiography, is
highest in the medial amygdala, followed by the
ventromedial nucleus, preoptic area and arcuate
nucleus (Morrell et al., 1986). Immunocytochemical
studies of estrogen receptor alpha protein have found
a roughly similar pattern (e.g., Wood and Newman,
1995). The development of antibodies and mRNA
detection methods for localization of estrogen recep-
tors has provided enhanced sensitivity for identifi-
cation of cells with lower levels of estrogen receptor
expression per cell, as is characteristic for estrogen tar-
get areas that are not classically identified with repro-
duction. Although the amount of estrogen receptor per
cell and the total proportion of cells that are estrogen
targets in areas such as the cerebral cortex, hippocam-
pal formation, and midbrain raphe may be lower than
found in the hypothalamus and amygdala, nevertheless
the total number of such cells may in fact be much
greater overall than found in the hypothalamus-preop-
tic continuum and amygdala. Therefore, the potential
impact of estrogen, via estrogen receptor activation, in
extra-hypothalamic, extra-amygdaloid regions should
not be underestimated.
There is little doubt that the preponderance of high-
level estrogen receptor expression, that is amount of
protein per cell, occurs in neurons under normal con-
ditions. A steroid autoradiographic study, using a
highly sensitive iodinated synthetic estrogen, showed
that estrogen concentrating cells are immunopositive
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for neurofilament protein, but not glial fibrillary acidic
protein (Brown et al., 1993). However, as discussed
below, low levels of estrogen receptor immunoreactiv-
ity have been identified in oligodendrocytes and astro-
cytes of the hypothalamus, using ultrastructural
techniques (Langub and Watson, 1992). Moreover,
using confocal microscopy to detect cells double
labeled for estrogen receptor and glial markers, estro-
gen receptors have been identified in astrocytes (Azcoi-
tia et al., 1999c), microglia (Mor et al., 1999) and a
variety of other glial cell types (Gudino-Cabrera and
Nieto-Sampedro, 1999). Given that glial cells outnum-
ber neurons, it is possible that more glial cells express
estrogen receptor than do neurons, albeit at much
reduced levels. Quantitative studies to determine the
proportion of specific glial cell types that express estro-
gen receptor alpha and beta, and the frequency of
these cells in dierent brain regions, remain to be per-
formed.
In many regions of the adult rat nervous system,
levels of ER-a mRNA expression are higher in females
than in males. Generally, estrogen down-regulates ER-
a mRNA, but even when estrogen levels are at their
highest and ER levels at their lowest, adult females
exhibit higher levels of ER-a mRNA (Simerly and
Young, 1991; Shughrue et al., 1992) and ER protein
(Zhou et al., 1995) than do males; males apparently
have a lower capacity to synthesize ER. It is not
known whether this sex dierence in synthetic capacity
is limited to specific brain regions and normal versus
injured brains. To date, there is little information
about hormonal regulation and sexual dierentiation
of ER-b expression.
With regard to neuroprotection and estrogen recep-
tor regulation, aromatase levels (Garcia-Segura et al.,
1999a) and estrogen receptor levels (Dubal et al., 1999)
are upregulated following injury to the central nervous
system. We would have predicted that increases in
local estrogen synthesis would be accompanied by
decreased ER synthesis, the opposite of what actually
occurs. The increase in ER-a expression is restricted to
those areas that express high levels of ER during
development. Together, these data support the argu-
ment that injury initiates a survival response that
requires enhanced levels of both ligand and receptor.
What neurotransmitters or other factors are released
upon injury and participate in the upregulation or dis-
inhibition of estrogen receptor synthesis is an open
question. Noradrenaline is one neurotransmitter impli-
cated in modulation of estrogen receptor levels and re-
sponses to estrogen under normal conditions (Clark et
al., 1985; Tetel and Blaustein, 1991).
The localization of estrogen receptors is not the only
factor determining the role of estrogen within a given
area. Estrogen receptor activation has regionally
specific consequences. A key example of this is found
in the anteroventral preoptic area (AvPv) and sexually
dimorphic nucleus of the preoptic area (SDN-POA).
Both areas express estrogen receptors during develop-
ment (Kuhnemann et al., 1994; DonCarlos and
Handa, 1994; DonCarlos et al., 1995), and are func-
tionally related, yet estrogen promotes survival of
SDN-POA neurons (Dohler et al., 1984) and death of
AvPv neurons (Arai et al., 1996; Davis et al., 1996). In
addition to demonstrating that estrogen can exert
opposite eects in related estrogen receptor expressing
regions, these findings also serve to underscore the fact
that estrogen may not be universally neuroprotective.
3.2.2.3. Estrogen receptor mediated neuroprotection.
Several lines of evidences suggest that neuroprotective
eects of estradiol may be at least in part mediated by
the activation of estrogen receptors. The neurotrophic
action of estradiol in primary hippocampal cultures is
reduced by substances, such as geldanamycin, that dis-
rupt mature steroid receptor complexes (Gold et al.,
1999). Molybdate (20 mM), which prevents the disrup-
tion of mature steroid receptor complexes, also
decreases the neurotrophic activity of estradiol (Gold
et al., 1999). This finding indicates that components of
steroid receptor complexes may be involved in the neu-
roprotective eect of the hormone. A direct proof of
the involvement of estrogen receptor on cell survival
has been obtained in PC12 cells. Estrogen enhances
the survival of PC12 cells transfected with the full-
length rat estrogen receptor alpha, but does not aect
the survival of control cells transfected with vector
DNA alone (Lustig, 1996; Gollapudi and Oblinger,
1999a; 1999b). There is also evidence that estrogen
receptor is involved in the regulation of neuronal sur-
vival in primary cultures. Estrogen enhancement of
neuronal survival in primary hypothalamic cultures in
the serum-free medium and in cortical cultures exposed
to glutamate is blocked by the estrogen receptor antag-
onists tamoxifen (Chowen et al., 1992; Singer et al.,
1996b) and ICI 182, 780 (Duen˜as et al., 1996; Singer et
al., 1999). In addition, antiestrogens abolish the neuro-
protective action of 17b-estradiol in cultures of dorsal
root ganglion neurons deprived of nerve growth factor
(Patrone et al., 1999). All of these findings provide evi-
dence that estrogen may promote neuronal survival in
vitro by an eect mediated via estrogen receptors. The
dependence of neuroprotective eects of estradiol on
estrogen receptors has been demonstrated in vivo as
well. The intracerebroventricular administration of the
estrogen receptor antagonist ICI 182, 780 inhibits the
neuroprotective eect of estradiol in hippocampal hilar
neurons of ovariectomized rats exposed to systemic
kainic acid (Azcoitia et al., 1999b). Furthermore, the
selective estrogen receptor modulator raloxifene pre-
vents MPTP-induced dopaminergic depletion in mice
(Grandbois et al., 2000).
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3.2.3. Potential molecular targets of estrogen receptor-
mediated neuroprotection
3.2.3.1. Regulators of synaptic sprouting and axonal re-
generation. It is well established that estradiol regulates
synapse formation during development and induces
synaptic plasticity in the adult brain (Matsumoto,
1991; Garcia-Segura et al., 1994; McEwen, 1996;
Woolley, 1998). These hormonal eects are involved in
the sexual dierentiation of synaptic connectivity and
in the physiological regulation of adult brain function.
In addition, since the pioneering work of Matsumoto
and Arai (1979), it has been known that estrogen may
promote synaptic sprouting in response to injury.
These authors tested the eect of estrogen in the arcu-
ate nucleus after deaerentation, a treatment that
results in a loss of axo-dendritic synapses. Treatment
with estradiol benzoate for three weeks, beginning on
the day of surgery, eectively restored the axodendritic
synaptic population of the deaerented arcuate nucleus
in adult ovariectomized rats (Matsumoto and Arai,
1979, 1981). Further studies have shown that the arcu-
ate nucleus of aged female rats still retains plasticity to
react to deaerentation under the influence of estrogen
(Matsumoto et al., 1985). Other studies have shown
that estrogen enhances synaptic sprouting in the hip-
pocampus of ovariectomized female rats after entorh-
inal cortex lesions (Morse et al., 1986, 1992) and that
estrogen accelerates regeneration rates of injured facial
motoneurons (Tanzer and Jones, 1997).
Many dierent molecules, including cytoskeletal
components, adhesion molecules and soluble factors,
participate in the process of axonal growth and axonal
target recognition. These molecules include growth fac-
tors and neurotrophins (Fig. 4). The possible role of
growth factors and neurotrophins in the neuroprotec-
tive eects of estradiol is discussed in Section 3.2.3.3.
Little is known about the role of adhesion and gui-
dance molecules, such as semaphorins, on the neuro-
protective eects of estradiol. In contrast, it is known
that estradiol induces the expression of tau in axons
and this may result in the stabilization of microtubules
and the promotion of axonal growth (Ferreira and
Caceres, 1991; Lorenzo et al., 1992; Diaz et al., 1992).
Another protein that may be involved in estrogen-
induced axonal regeneration is GAP-43. GAP-43, also
known as B-50, is a presynaptic protein implicated in
the growth and regeneration of axons (Oestreicher et
al., 1997). The expression of GAP-43 is modulated by
estrogen in the preoptic area of developing and adult
rats (Shughrue and Dorsa, 1993) and in the medioba-
sal hypothalamus of adult rats (Lustig et al., 1991).
Levels of GAP-43 decline in aged rats. Interestingly,
estrogen restores GAP-43 mRNA in 24 month old rats
to levels comparable to that seen in young animals
(Singer et al., 1996a).
The eect of estrogen on synaptic sprouting may be
mediated by the up-regulation of ApoE expression
(Stone et al., 1998a; Teter et al., 1999). ApoE is
involved in lipid and cholesterol metabolism and it
may be involved in the mobilization and reutilization
of lipid in the repair, growth, and maintenance of my-
elin and axonal membranes, both during development
and after injury. Furthermore, the epsilon 4 allele of
ApoE has a direct impact on cholinergic function in
Alzheimer’s disease (Poirier, 1994; see also Section
2.1.2). The synthesis of ApoE is dramatically increased
after injury of peripheral nerves (Ignatius et al., 1986;
LeBlanc and Poduslo, 1990) and in the central nervous
system (Poirier, 1994). Although nerve regeneration
may occur in ApoE deficient mice (Popko et al., 1993;
de Chaves et al., 1997), these animals show an
increased central neuronal damage after cerebral ische-
mia and other forms of cerebral injury (Chen et al.,
1997a, 1997b; Sheng et al., 1999; Horsburgh et al.,
1999), suggesting that ApoE may be a factor involved
in brain repair. Stone et al. (1998a) have shown that
estrogen enhances synaptic sprouting in response to an
entorhinal cortex lesion in wild-type and not in ApoE-
knock-out mice. Furthermore, synaptic sprouting is
increased by estrogen in the same regions where
sprouting is dependent on ApoE (Teter et al., 1999).
3.2.3.2. Regulators of cell death. Estrogen’s neuropro-
tective eects may involve, at least in part, a modu-
lation of the expression of molecules involved in the
control of cell death (Figs. 4 and 5). The family of
Bcl-2-related proteins is involved in the regulation of
cell death of many cell types, including neurons. Some
members of this family are negative regulators of cell
death, such as Bcl-2 and Bcl-XL. Other members, such
as Bax and Bad, are positive regulators of cell death.
Estradiol has been shown to promote the expression of
Bcl-2 in NT2 neurons (Singer et al., 1998) and in adult
neurons in vivo (Garcia-Segura et al., 1998) and the
expression of Bcl-XL in PC12 cells (Gollapudi and
Oblinger, 1999a; Gollapudi and Oblinger, 1999b) and
Fig. 5. Described eects of estradiol on molecules that regulate pro-
grammed cell death. Estradiol downregulates the proapoptotic mol-
ecules Nip-2 and Par-4 and upregulates the antiapoptotic molecules
Bcl-2 and Bcl-XL in neurons and neuronal cell lines. Acting on Bcl-
2, estradiol may directly aect neuronal survival by blocking caspase
activation and indirectly by the promotion of axonal regeneration.
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in cultured hippocampal neurons (Pike, 1999). Identifi-
cation of estrogen receptor target genes by mRNA
dierential display PCR in human neuroblastoma SK-
ER3 cells has revealed that the mRNA for the Bcl-2
interacting protein Nip2 is decreased by estrogen treat-
ment (Garnier et al., 1997). Nip-2 expression is also
down-regulated by estradiol in monoblastoid cells
(Vegeto et al., 1999). Since Nip2 is a negative regulator
of Bcl-2, estrogen may promote Bcl-2 expression by
this mechanism (Fig. 5). In addition, estradiol may
directly aect transcription of bcl-2 gene, since several
putative estrogen-responsive sites are present in the
bcl-2 promoter (Teixeira et al., 1995).
The hormonal regulation of the expression of the
members of the Bcl-2 family is associated with the neu-
roprotective eects of estradiol. For instance, estradiol
enhances the survival of PC12 cells transfected with
the full-length rat estrogen receptor alpha and this
eect is associated with an increased expression of Bcl-
XL and a reduced expression of Bad (Gollapudi and
Oblinger, 1999b). An increased expression of Bcl-2 is
associated with the hormonal protection of NT2 neur-
ons from H2O2 or glutamate induced cell death (Singer
et al., 1998). Estrogen significantly increases the ex-
pression of the antiapoptotic protein Bcl-XL in cul-
tured hippocampal neurons and this induction is
associated with a reduction in apoptosis induced by
beta-amyloid (Pike, 1999). Furthermore, 17b-estradiol
increases survival of cultured dorsal root ganglion
neurons deprived of nerve growth factor and this eect
is associated with an increased expression of Bcl-X
without aecting the expression of Bax (Patrone et al.,
1999). Dubal et al. (1999) have found that estradiol
prevents the down regulation of bcl-2 expression in the
rat cerebral cortex induced by ischemia. Since this
eect is accompanied by an increased ratio of estrogen
receptor beta/estrogen receptor alpha expression,
Dubal et al. (1999) propose that estradiol decreases the
extent of cell death after ischemia by an estrogen
receptor-beta mediated eect on Bcl-2. In addition to
preventing neuronal death, Bcl-2 may also promote
axonal growth and axonal regeneration (Chen et al.,
1997a, 1997b; Holm and Isacson, 1999). Therefore, by
the induction of Bcl-2, estradiol may promote neuronal
survival after injury both by Bcl-2-induced inhibition
of cell death and by Bcl-2-induced facilitation of regen-
eration of neuronal connectivity (Fig. 5). Furthermore,
Bcl-2 attenuates the generation of reactive oxygen
species (Bogdanov et al., 1999) and estradiol may
therefore reduce oxidative stress in neural tissue by the
induction of Bcl-2 expression.
Another protein that regulates cell death and is a
target of estradiol is the prostate apoptosis response-4
(Par-4), the product of a gene up-regulated in prostate
cancer cells undergoing apoptosis. Par-4 expression is
induced in neurons after exposure to trophic factor
deprivation and apoptotic insults (Guo et al., 1998;
Chan et al., 1999; Duan et al., 1999a, 1999b) and is
up-regulated in vulnerable neurons in Alzheimer’s dis-
ease brains (Guo et al., 1998). Par-4 antisense treat-
ment suppresses mitochondrial dysfunction and
caspase activation in synaptosomes and prevents cell
death of cultured hippocampal neurons following ex-
posure to excitotoxic and apoptotic insults (Duan et
al., 1999a). Interestingly, both Par-4 induction and cell
death induced by trophic factor deprivation in cultured
hippocampal neurons are largely prevented by pre-
treatment of the cultures with 17b-estradiol (Chan et
al., 1999). Since increases in Par-4 expression follow an
increase of reactive oxygen species, and precede mito-
chondrial membrane depolarization, caspase acti-
vation, and nuclear chromatin condensation/
fragmentation, the down-regulation of Par-4 ex-
pression by estrogen may be one of the mechanisms
involved in the antioxidant and neuroprotective eects
of the hormone (Fig. 5).
3.2.3.3. Growth factors
Neurotrophins. Since the pioneering work of Toran-
Allerand et al. (1992a, 1992b), it has been well estab-
lished that estrogen and neurotrophins interact in
many areas of the nervous system. Estrogen regulates
the expression of neurotrophins and their receptors
and neurotrophins regulate the expression of estrogen
receptors in dierent neuronal populations. For
instance, nerve growth factor significantly increases
nuclear estrogen binding in cortical explants (Miranda
et al., 1996). In turn, estrogen regulates the expression
of p75 and of trkA in dorsal root ganglion neurons
from adult rats (Sohrabji et al., 1994a) and in PC12
cells (Sohrabji et al., 1994b). The hormone regulates
the expression of mRNA for brain-derived neuro-
trophic factor and nerve growth factor in the hippo-
campus and frontal cortex (Simpkins et al., 1997a),
decreases the expression of NGF in the hippocampus
and of trkA in the medial septum and nucleus basalis
magnocellularis (Gibbs et al., 1994) and increases the
expression of trkA in the basal forebrain of adult
female rats (McMillan et al., 1996). By decreasing the
expression of brain-derived neurotrophic factor, estro-
gen induces dendritic spine growth in hippocampal
neurons (Murphy et al., 1998). This co-regulation of
neurotrophins and estrogen receptors may be regulated
by cell to cell interactions or may occur in the same
neuron, since estrogen receptors and neurotrophin
receptors are coexpressed in some cells.
In 1992, Toran-Allerand et al. reported that estrogen
receptors colocalize with p75, the low-anity nerve
growth factor receptors, in cholinergic neurons of the
basal forebrain (Toran-Allerand et al., 1992b). Further
studies have shown a widespread colocalization of es-
trogen and neurotrophin receptors within estrogen and
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neurotrophin targets, including neurons of the cerebral
cortex, sensory ganglia and PC12 cells (Sohrabji et al.,
1994a, 1994b; Miranda et al., 1994; Toran-Allerand,
1996; Toran-Allerand et al., 1999). These findings indi-
cate that estrogen and growth factors may act in con-
cert on the same neuron to regulate the expression of
specific genes that may influence neuronal survival
(Toran-Allerand et al., 1992b; Toran-Allerand, 1996).
Furthermore, the colocalization of estrogen receptors
and neurotrophin receptors in the same neurons leads
to convergence or cross-coupling of their signaling
pathways. In addition, estradiol may directly activate
the signaling pathways of growth factors without the
involvement of intracellular estrogen receptors. For
instance, estradiol has been shown to elicit rapid and
sustained tyrosine phosphorylation and activation of
the mitogen-activated protein kinases ERK1 and
ERK2 in cerebral cortical explants and neuroblastoma
cells. ERK activation is not inhibited by the estrogen
receptor antagonist ICI 182,780 and may depend on
an increase in B-Raf kinase activity (Watters et al.,
1997; Singh et al., 1999; Toran-Allerand et al., 1999).
In addition, estrogen induced neuroprotection in pri-
mary cortical cultures exposed to glutamate is associ-
ated with a rapid activation of tyrosine kinase and
MAPK activity (Singer et al., 1999).
It is still unknown whether estrogen and neurotro-
phins act in concert to promote neuronal survival after
neural injury in vivo. However, an interaction of estro-
gen and NGF has been documented in terminally dif-
ferentiated PC12 cells transfected with the estrogen
receptor alpha. Estrogen and NGF act synergistically
to protect these cells from apoptosis induced by serum
deprivation (Gollapudi and Oblinger, 1999b). This
synergistic eect was not observed in control PC12
cells transfected with vector DNA (Gollapudi and
Oblinger, 1999b), suggesting that the synergistic action
of estrogen and NGF on neuroprotection is dependent
on estrogen receptor. Further studies are still needed
to determine the extent of the interaction of estrogen
and neurotrophins in dierent models of brain injury.
Insulin-like growth factor I. Insulin-like growth factor
I (IGF-I) has prominent neurotrophic eects, stimulat-
ing dierentiation and survival of specific neuronal
populations (Torres-Aleman et al., 1990, 1994; Beck et
al., 1995; De Pablo and De la Rosa, 1995). Trophic
eects of IGF-I are mediated by IGF-I receptor, a
member of the growth factor tyrosine kinase receptor
family that signals through the phosphoinositol-3
kinase pathway and the mitogen-activated protein
kinase (MAPK) cascade. IGF-I and estrogen have
interactive eects on neurons. The first evidence for
this was provided by Toran-Allerand et al. (1988),
showing that in explant cultures of fetal rodent hypo-
thalamus, estrogen and insulin have a synergistic
action on neuritic growth, an eect probably mediated
by IGF-I receptors. Subsequent studies showed that
estrogen modulates IGF-I receptors and binding pro-
teins in monolayer hypothalamic cultures (Pons and
Torres-Aleman, 1993). Both IGF-I and estrogen pro-
mote survival and dierentiation in primary hypo-
thalamic cultures. Interestingly, in this system the
eect of estrogen is dependent on IGF-I and the eect
of IGF-I is blocked by the estrogen receptor antagon-
ist ICI 182, 780 (Duen˜as et al., 1996). Furthermore,
IGF-I receptor activation is necessary for estrogen in-
duction of glial and synaptic plasticity in the hypo-
thalamus in vivo (Fernandez-Galaz et al., 1997, 1999).
The possible interaction of the neuroprotective
eects of estradiol and IGF-I after injury have also
been tested in vivo, by assessing neuronal survival in
the hilus of the dentate gyrus after systemic adminis-
tration of kainic acid to ovariectomized rats. Either
IGF-I or estradiol is able to protect hippocampal neur-
ons from kainic acid-induced degeneration (Azcoitia et
al., 1998, 1999b). The administration in the lateral cer-
ebral ventricle of a specific IGF-I receptor antagonist,
the peptide JB1, resulted in the prevention of the neu-
roprotective eects of estrogen in this model, indicat-
ing that the hormonal eect is dependent on IGF-I
receptors. Furthermore, the neuroprotective eect of
IGF-I was blocked by ICI 182,780, indicating that ac-
tivation of estrogen receptors is necessary for the eect
of IGF-I on hippocampal neurons. These findings
suggest that the neuroprotective eect occurs only
when both IGF-I receptor and estrogen receptor sig-
naling pathways are activated. Since the production of
estrogen and its precursor androgens, as well as the
production of IGF-I, decline with aging in humans
(Lamberts et al., 1997), the interaction of estrogen and
IGF-I signaling in neuroprotection may be relevant to
the increased vulnerability to neurodegeneration in old
age.
Several points of convergence of IGF-I and estradiol
signaling may be involved in neuroprotection. For
instance, both estradiol and IGF-I activate MAPK.
MAPK interferes with c-Jun N-terminal protein kinase
activation, protecting cells from apoptosis (Cheng and
Feldman, 1998). On the other hand, it has been shown
that IGF-I and other growth factors may activate es-
trogen receptors in dierent cell types, including SK-
ER3 neuroblastoma cells transfected with the estrogen
receptor. This activation may occur even in the
absence of estradiol and it is exerted via the ras-path-
way in SK-ER3 neuroblastoma cells (Agrati et al.,
1997). Therefore IGF-I may in part regulate neuropro-
tection by direct activation of estrogen receptors.
Other possible molecules that may be involved in the
convergence of estrogen and IGF-I actions are those
of the Bcl-2 family, since both estradiol and IGF-I
induce the expression of the antiapoptotic regulator
Bcl-2 in adult rat brain (Garcia-Segura et al., 1998;
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Fernandez et al., 1999). Another possible common tar-
get for estrogen and IGF-I is NF-kB. This transcrip-
tion factor may be involved in the protection of
neurons from excitotoxic injury, oxidative stress and
amyloid-beta induced neuronal death (Heck et al.,
1999; Kaltschmidt et al., 1999; Yu et al., 1999). NF-kB
mediates IGF-I induced neuroprotection (Heck et al.,
1999), the p65 subunit of NF-kB heterodimer represses
estrogen receptors via a physical interaction (McKay
and Cidlowski, 1998), estrogen activates kB-specific
proteins in the uterus (Shyamala and Guiot, 1992) and
estrogen receptor alpha may regulate the expression of
genes under the control of NF-kB response elements
(Cerillo et al., 1998).
3.3. Glia versus neurons
Estrogen may directly or indirectly target cellular
components of the nervous system other than neurons.
Indeed, the protective eect of estradiol in transient
forebrain ischemia may be related in part to an
improvement of the vasodilating capacity (Hurn et al.,
1995; Pelligrino et al., 1998) and to prevention of
brain capillary endothelial cell loss which may in turn
reduce focal ischemic brain damage (Shi et al., 1997).
In addition, chronic estrogen depletion by ovariectomy
enhances leukocyte adhesion in the rat cerebral circula-
tion while estrogen repletion is accompanied by a sig-
nificant reduction in leukocyte adhesion (Santizo and
Pelligrino, 1999).
Glial cells are an essential component of normal
neural function as well as of the response of neural tis-
sue to injury. There is now substantial evidence that
glial cells are targets for steroid hormones (Garcia-
Segura et al., 1996; Jordan, 1999; Langub and Watson,
1992; Nichols, 1999; Vardimon et al., 1999; Finley and
Kritzer, 1999) and participate in steroid synthesis
(Koenig et al., 1995; Zwain and Yen, 1999) and
metabolism (Melcangi et al., 1999). Glial cells mediate
dierent actions of gonadal steroids in the regulation
of the development and plasticity of specific neuronal
populations and in the control of neuroendocrine
events (Garcia-Segura et al., 1996, 1999b; Jordan,
1999; Melcangi et al., 1999; Mong and McCarthy,
1999; Ojeda and Ma, 1999). Furthermore, glial cells
may be involved in the regenerative and neuroprotec-
tive eects of gonadal hormones (Garcia-Segura et al.,
1999b; Jones et al., 1999; Melcangi et al., 1999;
Nichols, 1999).
Estrogen receptors have been detected in dierent
populations of glial cells (Azcoitia et al., 1999c;
Gudino-Cabrera and Nieto-Sampedro, 1999; Mor et
al., 1999) and estrogen regulates the morphology and
gene expression of glia (Garcia-Segura et al., 1996,
1999b; Stone et al., 1998b). Furthermore, estrogen
may regulate the proliferation of glia and the for-
mation of reactive gliosis: the hormone inhibits micro-
glia proliferation in vitro (Ganter et al., 1992) and
down-regulates the proliferation of astrocytes after
injury and the accumulation of reactive astrocytes in
the lesioned brain area in both male and female rats
(Garcia-Estrada et al., 1993, 1999). These eects of es-
trogen on gliosis may be a contributing factor for
neural regeneration. Estrogen may regulate the pro-
duction of cytokines by the gliotic tissue that may be
deleterious for neurons. For instance, estradiol
decreases the activation of NF-kB in cultured rat
astroglial cultures following exposure to amyloid
beta(1–40) and lipopolysaccharides (Dodel et al.,
1999). Although NF-kB expression in neurons may
promote neuroprotection (see ‘‘Neurotrophins’’, p. 45),
this transcription factor is also a potent immediate-
early transcriptional regulator of numerous proinflam-
matory genes. Estrogen may therefore decrease the
inflamatory response after brain injury by decreasing
the activation of NF-kB in astrocytes. In addition, by
acting on glial cells, estrogen may regulate the release
of factors, such as growth factors and neurotrophins,
that promote neuronal survival and axonal regener-
ation. One of these factors is ApoE (see Sections 2.1.3
and 3.2.3.1). As mentioned before (Section 3.2.3.1),
ApoE is involved in the eects of estrogen on axonal
sprouting. Interestingly, estrogen increases the ex-
pression of ApoE in astrocytes and microglia in vitro
and in vivo (Stone et al., 1997), suggesting that these
two glial cell types may be involved in the reparative
eects of estrogen in the central nervous system. Since
immunoreactivity for estrogen receptor beta has been
detected in both microglia and astroglia (Azcoitia et
al., 1999c; Mor et al., 1999), it is possible that estrogen
may directly act on these cells to regulate the pro-
duction of ApoE.
Glial cells, in addition to mediating hormonal
eects, may also produce neuroprotective steroids,
including estradiol. Aromatase, the enzyme that pro-
duces estrogen from androgen precursors, is induced
de novo in astrocytes by the systemic administration
of kainic acid or by introducing a cannula in the brain
parenchyma of rats and mice (Garcia-Segura et al.,
1999a). This finding suggests that local production of
estrogen is one of the mechanisms used by the central
nervous system to cope with neurodegeneration and
emphasizes the significance of estradiol as a neuropro-
tectant (Fig. 6).
4. Prospectives for future studies
4.1. Estrogen and adult neurogenesis
The ability to induce proliferation and functional in-
corporation of new neurons in the adult brain would
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represent the ultimate form of neuroprotection. It has
been understood for some time that new neurons are
in fact born and functionally incorporated into the
olfactory neuroepithelium. More recently, adult neuro-
genesis has been recognized in many species and more
than one brain region (Alvarez-Buylla and Lois, 1995),
including the higher vocal center of song birds where
neurons are replaced seasonally (Barnea and Notte-
bohm, 1994; Alvarez-Buylla and Kirn, 1997), and the
dentate gyrus of the hippocampal formation of mam-
mals, where it was first observed by Altman and Das
(1965).
A potential role for estradiol in production of hip-
pocampal granule cells has been investigated by Gould
et al. (1999). These investigators found that, following
injection with bromodeoxyuridine (BrdU), a thymidine
analog that labels dividing cells, females had signifi-
cantly more newly generated cells in the dentate gyrus
than did males. The delay between final division and
incorporation into the granule cell layer was approxi-
mately 3 weeks. By 3 weeks (and even earlier), there
was no overall sex dierence in the total number of
granule neurons, perhaps because more of the newly
generated cells die in females. Neurogenesis is not only
dierent in males and females, it also fluctuates with
the estrous cycle. The number of newly generated cells
in the dentate gyrus was 50% higher in females
injected with BrdU on proestrus (estradiol levels high)
versus females injected on estrus or diestrus (estradiol
levels low). Estrogen treatment reversed ovariectomy
induced decreases in the rate of neurogenesis. More-
over, the number of dying cells is altered by circulating
hormones, since 40% fewer pyknotic cells were
observed in proestrus females vs those sacrificed at
other stages of the cycle. Similarly, some investigators
have found that estrogen promotes survival of newly
generated neurons in the bird song control regions
(Hidalgo et al., 1995; Burek et al., 1995). Estrogen-
induced alterations in neurogenesis may be direct or
may involve estrogen-dependent modifications of the
hypothlamo-pituitary-adrenal axis, since adrenal ster-
oids inhibit proliferation of cells destined for the gran-
ule cell layer (Gould et al., 1992), but this remains to
be established. Brief mention should be made respect-
ing one potential technical caveat in evaluating those
studies that use BrdU as a marker for newly generated
cells, particularly with respect to eects of estrogen on
the genesis and survival of neurons. Kolb et al. (1999)
recently reported that BrdU is toxic to the embryonic
brain. Also, earlier reports had shown that BrdU inter-
feres with estrogen signaling (Kallos et al., 1978; Gar-
cia et al., 1981). Confirmation of BrdU results with
results based on other techniques to identify prolifera-
tive populations is therefore warranted.
The functional significance of continual replenish-
ment of dentate granule cell neurons, and why estro-
gen modifies replacement of neurons in the dentate
gyrus is unknown. One proposal is that the continuous
replacement of neurons in the dentate gyrus provides a
refreshable repository for temporary processing of new
information that is later moved elsewhere for long
term storage (Tanapat et al., 1999). Neuron addition
in the hippocampal formation does appear to be accel-
erated under conditions that require or enhance learn-
ing (Gould et al., 1999; Huang et al., 1998;
Kempermann et al., 1997), as observed in the avian
vocal control pathways (Nordeen, 1990; Alvarez-
Buylla and Kirn, 1997). Higher estradiol levels may
signal a physical (e.g. pregnancy) or environmental
(e.g. change of season) challenge that requires augmen-
ted memory acquisition. Since neurogenesis in the hip-
pocampus declines with age (Cameron and McKay,
1999), as do estrogen levels at menopause, these con-
current events may precipitate decreased cognitive
functioning with age in some individuals.
Potential estrogen-dependent alterations of neuro-
genesis may also be of considerable clinical interest
with the development of neural stem cell technology
for replacing lost neurons. In hamsters, androgens
enhance the functional incorporation into the olfactory
bulb of progeny derived from the subventricular zone
(Huang et al., 1999), and in mice, the hormones of
pregnancy enhance neurogenesis (Kaba et al., 1988).
Estrogen may help to coax the dierentiation of en-
dogenous or exogenously applied neural stem cells into
regionally appropriate and transmitter specific pheno-
types. One potential mechanism through which estro-
gen may modulate neuropoiesis could involve
interactions with growth factors, as discussed in Sec-
tion 3.2.3.3. For example, estrogen upregulates ex-
pression of brain derived neurotrophic factor (BDNF)
Fig. 6. Possible sources of estradiol for injured neurons in the central
nervous system. Estradiol may reach neurons directly from the circu-
lation (1), after local conversion of peripheral testosterone by reac-
tive astroglia (2), and after local conversion of locally-formed
testosterone by reactive astroglia (3). Route 1 is of particular signifi-
cance in females while route 2 will be of particular significance in
males. Route 3 may operate in both sexes.
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mRNA and protein in numerous brain regions (Gibbs,
1999), including the cortex and hippocampal formation
(Singh et al., 1995). BDNF, in turn, promotes gener-
ation and survival of neurons derived from subventri-
cular zone precursors (Goldman, 1998; Zigova et al.,
1998). Exogenous epidermal growth factor (EGF) pro-
motes dierentiation of subventricular zone progeny
into astrocytes rather than neurons, whereas basic
fibroblast growth factor-2 (FGF-2) promotes an
increase in the total number of newborn cells and
development of a neuronal phenotype in progeny
(Kuhn et al., 1997; Palmer et al., 1999) in the rat, and
like other neurotrophic factors (Toran-Allerand, 1996),
may be regulated by estrogen in the brain. Therefore,
it is conceivable that estrogen will modulate neuropoi-
esis and the fate of progeny via interaction with
growth factors. It is clearly of vital clinical importance
to evaluate the potential therapeutic role of estrogen in
stimulation of proliferation and survival of endogen-
ous neural stem cells, on the one hand, and on the
other hand, in orchestration of topographically accu-
rate migration and targeted dierentiation of trans-
planted neural stem cells.
4.2. Estrogen receptor regulation following injury
In development, estrogen receptors are transiently
expressed at high levels in some areas where they are
not expressed in adulthood, such as the facial motor
nucleus (Hayashi, 1994) or are expressed at much
lower levels in the adult than the neonate, as in the
hippocampal formation (O’Keefe and Handa, 1990;
O’Keefe et al., 1995). Neural repair has been proposed
to involve, in part, reinitiation of developmental pro-
grams by injured neurons. Estrogen receptors may
therefore play a role in survival or dierentiation of
neurons in these regions. Estrogen receptor expression
is induced following injury (Dubal et al., 1999) in
regions of the cerebral cortex that produce higher
levels of receptor developmentally (Shughrue et al.,
1990; Yokosuka et al., 1995), and may play a protec-
tive role in both instances. Estrogen accelerates recov-
ery of function of facial motor neurons following
axotomy (Tanzer and Jones, 1997), although recapitu-
lation of developmental estrogen receptor expression
does not appear to be involved (Tanzer et al., 1999).
Whether estrogen receptor induction following neuro-
logic impairment occurs only in those areas that
express the receptors during development or adulthood
or is a more global injury response is unknown. If es-
trogen receptors are proven to be uniformly beneficial
to the injury response, then, as discussed above for the
induction of neurogenesis, means by which estrogen
receptor expression can be selectively augmented in
targeted regions should be sought.
4.3. Estrogenic ligands, receptors, and other mechanisms
of action
A major area of current eort in endocrinology is
the search for ligands that selectively target estrogen
receptors in specific tissues and provide benefits, such
as prevention of osteoporosis or heart disease, without
promoting the development of hormone dependent
cancers. Similarly, estrogenic ligands that act in
specific regions on specific subsets of neurons or glia
would be ideal, not only to prevent the potentially
harmful peripheral eects of estrogen, but also because
the positive versus negative eects of estrogen within
the nervous system are likely to be brain region depen-
dent. For example, estrogen is toxic to neurons in the
arcuate nucleus of the hypothalamus, specifically those
that produce b-endorphin (Desjardins et al., 1995),
where it is thought to accelerate the onset of reproduc-
tive senescence. Additionally, in the sexually dimorphic
nucleus of the preoptic area of aging male rats, the
loss of neurons is more severe following estrogen treat-
ment (Hsieh et al., 1996). Developmentally, estrogen
has opposite eects on survival even in neighboring
and functionally related neuronal populations, where it
spares some neurons (for example, in the sexually
dimorphic nucleus of the preoptic area) while killing
others (anteroventral periventricular nucleus of the
preoptic area) (Arai et al., 1996).
The above discussion highlights the need to learn
more about the various mechanisms of action of estro-
gen in normal function as well as neuroprotection. If
the mechanism of action of estrogen is due to a non-
specific enhancement of neural activity, then the eects
of estrogen in neuroprotection should be similar to
those of other general stimulants. More needs to be
known about the anti-oxidant eects of estrogen, such
as the required dose, time-course, and best route of ad-
ministration for maximal benefits from estrogen treat-
ment. The eects of estrogen on blood flow and
cholesterol deposition similarly need further study. The
elusive membrane receptors for estrogen should be
explored further, to understand both their normal
function and whether activation of these membrane
receptors is neuroprotective. Why do exogenous, but
not endogenous, steroids protect (as demonstrated by
some castration experiments showing that castration
does not alter responses to lesion (e.g. Kujawa and
Jones, 1991; Kujawa et al., 1993). Jones and colleagues
(Jones et al., 2000) have argued that one mechanism
for steroid induced neuroprotection involves the heat
shock proteins, which form part of the steroid receptor
heteromeric complex in the ligand-free state. They
argue that when ligand causes the dissociation of heat
shock proteins from the receptor complex, the pool of
liberated heat shock protein can initiate signaling cas-
cades that accelerate regenerative responses following
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injury; similar mechanisms have been invoked by
Toran-Allerand et al. (1999). Thus, exogenous steroid
exposure may eliminate the need for de novo synthesis
of heat shock protein in response to injury. Studies to
overexpress heat shock proteins following injury may
answer this question.
Much remains to be learned about the regulation of
the nuclear estrogen receptors in the nervous system,
such as how expression of these receptors is altered by
cyclical and maturational shifts in hormones, preg-
nancy hormones, environmental cues, nutritional sta-
tus, and behaviors as well as by neural disease or
trauma. For those neuroprotectve eects that are
dependent on estrogen receptors, how are these recep-
tors regulated following damage? Is their regulation
specific to the type of damage incurred? Is recent ex-
posure to estrogen necessary to maintain estrogen sen-
stivity, such that acute estrogen treatment will not
sustain survival mechanisms in elderly women because
their estrogen receptor concentrations are too low? Are
sex dierences in mental and neurological disorders
correlated in some way with disturbances of steroid
receptor expressing areas specifically? What neuro-
transmitters regulate expression of estrogen receptors,
and do declines in specific neurotransmitters, for
example, serotonin, aect responses to estrogen?
Which specific coactivators or adapter proteins are
expressed in the nervous system and can their ex-
pression and regulation be manipulated to enhance the
neuroprotective eects of estrogen? Finally, the extent
to which sex dierences in developmental exposure to
steroid hormones alters responses to the protective
eects of estrogen in adulthood is unknown.
4.4. Optimal estrogen administration in neuroprotection
Clinically, what is the time course of estrogen ex-
posure required to promote protection? If very high
doses are necessary, are acute treatments sucient?
What is the eective window of time available to treat
patients with acute lesions, or does the hormone need
to be present at the time of injury to protect the brain?
Is exogenously delivered estrogen as eective as en-
dogenously formed hormone, and is it preferable, in
terms of protection of the brain and protection from
side eects, to administer a large, acute bolus of testos-
terone, and let the brain do the work of selecting the
site for local synthesis of estrogen? Clearly, there are
many questions to be addressed in future investi-
gations on the clinical ecacy of estrogen in treatment
of neurological diseases and injury.
5. Concluding remarks
Neuroprotection by estrogen holds great promise for
improving the clinical management of selected neuro-
degenerative diseases and neural trauma. Under nor-
mal conditions, estrogen has diverse pleiotropic eects
on the nervous system, beyond those eects that con-
stitute essential components of hypothalamo-pituitary-
gonadal regulation or the control of reproductive
behaviors. Similarly, the neuroprotective eects of es-
trogen might be expected to be diverse and broad-ran-
ging. The balance between protective and toxic levels
of estrogen may be lesion, region, and age-dependent,
and should be carefully investigated. The opposing
developmental eects of estrogen, promoting survival
in some cell populations and death in others, and the
negative impact of high levels of estrogen on survival
in aging neuronal populations, are powerful reminders
that caution must be used in predicting and exploiting
the potential therapeutically beneficial eects of estro-
gen on the nervous system.
Note added in proof
Since this review was prepared, two reports have
been published that call into question the therapeutic
use of estrogen in symptomatic Alzheimer’s disease
(Henderson et al., 2000; Mulnard et al., 2000). These
reports detail the results of separate randomized,
double-blind, placebo-controlled clinical studies
designed to test the potential of estrogen as a thera-
peutic agent in mild to moderate Alzheimer’s disease
patients. Although the length of treatment with conju-
gated equine estrogens was dierent in the two studies
(4 or 16 weeks in the Henderson et al., study, and 1
year in the Mulnard et al., study) the results were simi-
lar: estrogen treatment did not prevent cognitive
decline in women with mild to moderate Alzheimer’s
disease. In fact, estrogen treatment for 1 year was as-
sociated with a worsening of symptoms in these
patients. These findings agree with experimental data
indicating that estrogen is neuroprotective when
administered before or at the same time as the neuro-
degenerative stimulus but is not neuroprotective when
administered after the neurodegenerative stimulus. In
conclusion, both clinical and experimental data suggest
that estrogen may act as a preventive agent for neuro-
degeneration, while the hormone is probably unable to
act as a restorative agent in already degenerated neural
tissue.
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